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Abstract 
Lung cancer is the third most common cancer in the UK; 87% are histologically non-
small cell lung cancer (NSCLC). At the time of diagnosis, patients frequently have 
advanced disease, with poor one-year survival due to metastatic burden. The 
immune system should act as a key line of defence; recognising, killing and clearing 
malignant cells. However, ineffective immune responses contribute to cancer 
progression. Neutrophils are active players in the metastatic environment, but there 
is limited data regarding human neutrophil populations in advanced lung cancer. 
Greater understanding of the interplay between extrinsic cell signals and intrinsic 
cell features in determining neutrophil roles, is also needed.  
In this study, to investigate how the extrinsic metastatic NSCLC pleural environment 
influences the function of neutrophils, it was modelled in vitro by culturing healthy 
donor neutrophils in conditions emulating the pleural space. Tumour necrosis factor 
alpha (TNFa) and hypoxia acted as pro-survival signals leading to neutrophil 
persistence and NSCLC pleural fluid conditioned neutrophils to suppress CD8+ T 
cells through mechanisms including programmed death-ligand 1 (PD-L1) 
expression. To establish the phenotype of neutrophil populations in advanced 
NSCLC, neutrophils were extracted from the pleural fluid (metastatic site) and blood 
of patients. Cellular morphology, surface marker expression and functional assays 
were utilised. There was an expanded population of low-density blood neutrophils in 
advanced NSCLC, that were not present in health, and a proportion of which were 
immature with banded nuclei. Similar immature neutrophils were seen in NSCLC 
pleural fluid. NSCLC pleural fluid neutrophils expressed PD-L1 and were long-lived. 
To understand how cell-intrinsic features of neutrophil populations in advanced 
NSCLC may determine their role in cancer, the populations were defined by their 
transcriptomic and proteomic signatures. This provided evidence that implied 
NSCLC low-density blood neutrophils represent immature cells that have been 
recruited from the bone marrow; they may retain proliferative capacity, have reduced 
neutrophil granules, and are pro-survival.  
In summary, the data favours a phenotype of sustained neutrophilic inflammation 
that is immunosuppressive at the NSCLC metastatic site, with a subpopulation of 
immature cells that may be ineffective/ detrimental. This is likely to permit tumour 
progression, leading to adverse patient outcomes.   
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Lay Summary 
Lung cancer is the third most common cancer in the UK; 87% are a type called non-
small cell lung cancer (NSCLC). It is common for patients to have advanced disease 
at the time of diagnosis, where the cancer has spread to other organs 
(metastasised). The immune system should act as a key line of defence, 
recognising and killing cancer cells. Neutrophils (a form of white blood cell), should 
take part in this process. However, in advanced cancer, it is thought that neutrophils 
may not be helping in the ways that they should do, enabling cancer to progress/ 
metastasise. This could be due to changes in the inner programming of neutrophils 
and/ or a reaction to unhelpful signals in the metastatic tumour environment around 
them: this study aimed to gain further understanding of this. 
In this study, blood samples and pleural fluid were taken from patients with late-
stage NSCLC. Pleural fluid had collected in the space between the outer lining of 
the lung and the inner lining of the chest wall, as a result of cancer cells 
metastasising and growing there (cancer cells spread there by travelling in the blood 
and lymphatics from the tumour within the lung). Neutrophils were extracted from 
these tissues for studies that tested their appearance, cell surface features, function, 
and inner programming e.g. what proteins they had within them and were trying to 
make. The effect of the pleural environment upon neutrophils was also tested 
through simulation in the lab dish. These studies showed that signals in the 
metastatic NSCLC environment made neutrophils live longer. Pleural fluid also 
programmed neutrophils to supress other immune cells (CD8+ T cells) that normally 
act to kill cancer cells. An expanded subpopulation of immature cancer neutrophils 
was also identified in advanced NSCLC. This subpopulation was not present in the 
blood of healthy donors, and may be of functional importance in cancer. When the 
inner programming of cancer neutrophils was investigated, it revealed mechanisms 
that help the neutrophils to live longer. It also showed that the immature cancer 
neutrophil population had not yet made their cancer killing machinery and may be 
able to proliferate.  
Together this data implies that neutrophils in advanced NSCLC are unhelpful/ 
ineffective, for example, by living a long time, supressing cancer-killing immune cells 
and by lacking cancer killing machinery. The role of neutrophils in advanced NSCLC 
is determined by a combination of internal programming and external signals.  
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Chapter 1 Introduction 
 
1.1 The role of neutrophils in health 
Neutrophils are the most abundant white blood cell, forming 50-70% of circulating 
leukocytes. They play a central role in the innate immune response, acting to protect 
the body against infection, and responding at sites of tissue injury. Their importance 
is highlighted by immunodeficiencies, such as chronic granulomatous disease,1 that 
result in patients suffering from overwhelming infection. Appropriate neutrophil 
responses are dependent upon a functioning balance of neutrophil production, 
release from the bone marrow, recruitment to sites of need, activation and 
appropriate action at target sites, and effective clearance afterward. These factors 
are regulated by environmental signals. Dysregulation of this finely tuned 
homeostatic system results in disease. 
 
1.1.1 Neutrophil production and release 
A summary of neutrophil differentiation can be seen in Figure 1.1 (adapted from 
Hidalgo et al.2). Briefly, neutrophil differentiation behaves like a conveyor belt,3 with 
neutrophil-commitment starting with the promyelocyte which develops from the 
granulocyte macrophage progenitor in the bone marrow. Sequential steps of 
development then occur as per the figure (from left to right). Neutrophils develop 
granules (primary, secondary, tertiary) and their nuclei become more lobulated as 
they mature. Of key importance, from the metamyelocyte stage, the cells stop 
dividing. In health, only mature neutrophils are released from the bone marrow. 
However, during acute infection or inflammation, there is ‘left shift’ in the blood 
neutrophil population, with release of immature non-dividing cells into the 
circulation.4 Neutrophils are mobilised from the bone marrow by signals including 
granulocyte colony-stimulating factor (G-CSF). 
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Figure 1.1: Neutrophil development. 
The stages of neutrophil development are shown sequentially from left to right. From the 
metamyelocyte stage, the cells stop dividing. In health, only mature neutrophils are released 




1.1.2 Recruitment to tissues 
Once released from the bone marrow neutrophils circulate in the blood. At sites of 
inflammation, vascular endothelial cells are stimulated to express selectins. These 
capture neutrophils, binding to L-selectin. Neutrophils then roll along the 
endothelium before firmly adhering via integrins. They then transmigrate across the 
endothelium. Following this, neutrophils undergo chemotaxis, following signals (such 
as interleukin-8, interferon gamma, complement component 5a and leukotriene B4) 
to the site of need. Here neutrophils identify targets through pattern-recognition 
receptors (including Toll-like receptors), which sense pathogen-derived compounds 
(pathogen-associated molecular patterns, PAMPs) and ‘self’ danger signals 
(danger-associated molecular patterns, DAMPs). During these processes, 
neutrophils become activated and are subsequently stimulated into carrying out their 
defence functions.5  
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1.1.3 Neutrophil defence repertoire 
The neutrophil defence repertoire includes phagocytosis, degranulation, generation 
of reactive oxygen species and neutrophil extracellular trap formation. Phagocytosis 
is the process through which neutrophils engulf target materials and then degrade 
them within phagosomes.6 In terms of reactive oxygen species (formed in the 
respiratory burst), the enzyme nicotinamide adenine dinucleotide phosphate 
generates superoxide, which in turn is used to make hydrogen peroxide. 
Myeloperoxidase can then use hydrogen peroxide to produce hypochlorus acid. 
These reactive oxygen species are highly toxic to target microbes/ cells. Most of 
these processes occur within the safety of the neutrophil phagosome, but 
neutrophils can also release reactive oxygen species into their surroundings.7 
Through the process of degranulation, neutrophils can also release proteolytic 
enzymes and antimicrobial peptides.5 Finally, neutrophils can release a web of 
fibres composed of chromatin, DNA, histones and granular proteins, known as 
neutrophil extracellular traps, that immobilise and kill targets.8 
 
1.1.4 Apoptosis and clearance 
Apoptosis (programmed cell death) of neutrophils enables controlled clearance and 
resolution of inflammation, without any spilling of their toxic contents. Indeed, 
apoptotic neutrophils are commonly safely removed by being efferocytosed by 
macrophages.9 Neutrophils were traditionally thought to have a life span of less than 
24 hours, with a half-life of only 6-8 hours in the circulation.10 However more recent 
studies have suggested that they may persist for up to 5 days in the blood in 
health.11 Apoptosis is tightly controlled in neutrophils, and is mediated by both 
extrinsic and intrinsic pathways as seen in Figure 1.2 (adapted from Ichim et al.12). 
In the extrinsic pathway, eternal signals bind death receptors such as tumour 
necrosis factor-related apoptosis-inducing ligand receptor (TRAILR) and FS-7-
associated surface antigen (FAS). This leads to the activation of caspase-8 and 
caspase-10, that then in turn cleave and activate caspase-3 and caspase-7, which 
trigger apoptosis. In the intrinsic pathway, cell stress signals from within the cell, 
such as DNA damage and metabolic stress, stimulate B-cell lymphoma-2 homology 
domain 3-only protein (BH3-only protein) activation, triggering Bcl-2-associated X 
protein (BAX) and Bcl-2 homologous antagonist killer (BAK), resulting in 
mitochondrial outer membrane permeabilisation. This causes leak of mitochondrial 
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intermembrane space proteins that ultimately start a cascade of caspase activity 
that triggers apoptosis. The extrinsic pathway can also activate BAX and BAK 
through caspase-8 cleavage of BH3-interacting death domain agonist (BID). BAX, 
BAK and BID, are inhibited by pro-survival proteins B-cell lymphoma-2 (Bcl-2) and 
myeloid cell leukaemia-1 (Mcl-1).12 Of note, imbalance in apoptosis pathways can 
lead to prolonged and damaging neutrophilic inflammation. Several cytokines have 
been shown to stimulate neutrophil survival, including interleukin-1b, tumour 
necrosis factor, granulocyte-macrophage colony-stimulating factor, granulocyte 
colony-stimulating factor, and interferon-g.13 Tissue hypoxia also acts as a marked 
pro-survival neutrophil signal.14 
It must be noted that apoptosis is not the only mechanism of neutrophil death. The 
process of apoptosis requires adenosine triphosphate (ATP), and therefore 
energetic failure can lead to the failure of apoptosis. Furthermore, efferocytosis by 
macrophages may not be effective. In these circumstances, neutrophils can undergo 
necrosis, losing cytoplasmic integrity and leaking their toxic contents into the 
surrounding tissue. Finally, NETosis is a neutrophil death process distinct from 
apoptosis and necrosis. It involves the release of neutrophil extracellular traps 
(NETs), composed of chromatin and granule proteins, after cell membrane 
breakdown, and is dependent upon the generation or reactive oxygen species.15  
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Figure 1.2: Extrinsic and intrinsic apoptosis pathways. 
Apoptosis is tightly controlled in neutrophils, and is mediated by both extrinsic and intrinsic 
pathways. In the extrinsic pathway, external signals bind death receptors such as TRAILR 
and FAS, starting a cascade of caspase activity. In the intrinsic pathway, cell stress signals 
such DNA damage and metabolic stress, lead to mitochondrial protein leak, starting a 
cascade of caspase activity. TRAILR, tumour necrosis factor-related apoptosis-inducing 
ligand receptor; FAS, FS-7-associated surface antigen; BID, BH3-interacting death domain 
agonist; BH3-only, B-cell lymphoma-2 homology domain 3-only protein; BAX, Bcl-2-
associated X protein; BAK, Bcl-2 homologous antagonist killer; Bcl-2, B-cell lymphoma-2; 
Mcl-2, myeloid cell leukaemia-1.    
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1.2 The role of neutrophils in cancer 
The ability of malignant cells to establish themselves in a niche and subsequently 
metastasise is not entirely dependent on their own intrinsic cellular signaling 
pathways; complex interactions with a myriad of immune cells in the tumour 
microenvironment are key.16 It is now recognized that neutrophils are active players 
(rather than spectators) in the immune response to malignancy.17  
 
1.2.1 Association of neutrophils with cancer prognosis 
 
Neutrophil to lymphocyte ratio (NLR) 
Peripheral blood neutrophil counts increase in patients as their cancer progresses. 
Tumours produce granulocyte colony-stimulating factor (G-CSF) which skews the 
neutrophil retention/release balance in bone marrow, leading to this increase in 
blood neutrophils.18 G-CSF downregulates chemokine receptor type 4 (CXCR4) 
expression in human myeloid lineage cells, reducing their response to the bone 
marrow retention signal stromal cell-derived factor 1 (SDF-1).19  
Many research groups have investigated whether the number of neutrophils present 
in peripheral blood correlates with patient outcome. Most have done this using 
neutrophil to lymphocyte ratio (NLR). A meta-analysis of 100 such studies by 
Templeton et al. comprising over 40,000 patients, showed NLR>4 to be associated 
with worse overall survival, cancer specific survival, progression free survival and 
disease free survival.20 This was seen in all types and stage of cancer. 
 
Intra-tumoural neutrophils 
The association between peripheral blood neutrophils and survival does not 
however give any information about what might be happening at the tumour site 
itself i.e. whether tumour-associated neutrophils (TAN) are associated with outcome. 
A meta-analysis of nearly 4000 patients, has shown high levels of intra-tumoural 
neutrophils to be associated with unfavourable survival.21 In addition, Gentles et al. 
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used a computational approach to analyse bulk tumour transcriptomes in order to 
infer the frequency of different immune cell populations (including neutrophils) in 
over 3000 solid tumours (14 cancer types). They found intra-tumoural neutrophils to 
be the most adverse prognostic cell population.22 
 
Neutropaenia 
In direct contrast, neutropaenia in patients undergoing chemotherapy has been 
shown (by meta-analysis) to be beneficial to survival (despite the fact that 
neutropaenia also poses a risk of severe infection and associated mortality).23 This 
may of course just be a reflection of adequate toxicity of the drug being achieved to 
kill tumour cells, however the question does arise as to whether the direct effect on 
neutrophils themselves is beneficial. This is clinically relevant, as the use G-CSF in 
patients who are profoundly neutropaenic post chemotherapy (G-CSF used with the 
aim to prevent sepsis) could in fact be detrimental to longer term clinical outcome. 
Indeed, it has been shown that G-CSF may promote metastatic disease via 
neutrophils forming a pre-metastatic niche.24 
 
What about neutrophil function, site and regulation? 
Measuring the number of neutrophils in the blood and/or in the tumour of cancer 
patients and associating this with survival is of course quite a crude measure, and 
does not give any information regarding neutrophil function in cancer. It must also 
be remembered that blood neutrophil levels increase in other conditions, such as 
infection. Within the same patient, neutrophils may display varying roles at different 
sites. Furthermore, appropriate inflammatory responses are dependent upon a 
functioning balance of neutrophil production, release from bone marrow, recruitment 
to the site of injury and clearance. Dysregulation of this homeostatic process, for 
example by tumour derived G-CSF, could perpetuate malignancy.  
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1.2.2 Neutrophil polarisation 
 
Transforming growth factor beta (TGF-b) and interferon beta (IFN-b) have 
opposite effects on tumour-associated neutrophil (TAN) polarisation in mice 
Fridlender was the first to suggest that tumour-associated neutrophils (TANs) may 
be polarized to N1 (anti-tumour) or N2 (pro-tumour) phenotypes, in a similar manner 
to macrophages. Using tumour bearing mice, he demonstrated that TGF-b blockade 
favoured the accumulation of N1 TAN that were morphologically and functionally 
different to N2 TAN. N1 TAN had hypersegmented nuclei in contrast to the nuclei of 
N2 TAN that were circular. N1 TAN were cytotoxic to tumour cells via an oxygen 
radical-dependent mechanism and had increased tumour necrosis factor alpha 
(TNF-a) and intercellular adhesion molecule 1 (ICAM-1) expression, whereas N2 
TAN expressed high levels of arginase which is known to suppress T cell immunity. 
Of key importance, TGF-b blockade promoted a T cell anti-tumour response.25 
Using IFN-b1-/- tumour bearing mice, the Jablonska group have shown IFN-b to have 
the opposite effect to TGF-b on TAN polarisation i.e. IFN-b promotes anti-tumour N1 
TAN.26  
 
Limitations of N1 versus. N2 model 
It should be noted that the work described above in murine models is yet to be 
replicated in humans. Furthermore, in a similar manner to M1 versus M2 
macrophage classification in malignancy, it may be that a binary N1/N2 classification 
of neutrophils is an oversimplification.27 It seems increasingly likely that N1 and N2 
represent laboratory extremes of a biological continuum, with plasticity dependent 
upon the local environment.  
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1.2.3 Neutrophil roles in aiding or abating tumourigenesis 
Rather than focusing on N1/N2, we should possibly instead be defining neutrophils 
by the distinct functional phenotypes/subpopulations that aid or abate the process of 
tumourigenesis (e.g. proliferation, angiogenesis, invasion, immunosuppression and 
metastatic seeding) in the different microenvironments (i.e. primary tumour, 
circulation, pre-metastatic and metastatic). 
 
Tumour proliferation 
Neutrophil elastase (NE) has been shown to promote tumour proliferation. Houghton 
et al. showed that NE is taken up by tumour cells, where it degrades insulin receptor 
substrate-1 (IRS-1). Lower levels of IRS-1 were associated with an increase in the 
interaction between phosphatidylinositol 3-kinase (PI3K) and the potent mitogen 
platelet-derived growth factor receptor (PDGFR), which directed the PI3K axis to 
favour tumour proliferation.28  
In contrast neutrophils can also induce lysis of tumour cells via hypochlorus acid 
produced from reactive oxygen species (ROS).29 Of note, the MET proto-oncogene 
is expressed in neutrophils and is required for neutrophil chemoattraction and 
cytotoxicity toward tumour cells in response to its ligand hepatocyte growth factor 
(HGF).30 Neutrophils can kill tumour cells via TNF-a expression.26 Furthermore, 
neutrophils stimulated by interferons release tumour necrosis factor related 
apoptosis-inducing ligand (TRAIL) which induces tumour cell apoptosis. 31 32 
 
Angiogenesis and invasion 
The angiogenic and invasive mechanisms of matrix metallopeptidase 9 (MMP-9), 
vascular endothelial growth factor (VEGF) and Bv8 (prokineticin) have been 
previously described.33 34 It is thought that neutrophils may drive angiogenesis in 
malignancy by providing a significant source of MMP-9 which acts to release VEGF 
from the extracellular matrix (ECM).35 36 In addition to roles in angiogenesis, MMP-9 
is also postulated to aid the direct invasion of tumour cells via degradation of 
extracellular matrix/basement membrane.  
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Of note, it has been shown that neutrophil extracellular traps (NETs), formed during 
neutrophil death, and composing of chromatin, neutrophil elastase and 
myeloperoxidase, have a role in angiogenesis, by stimulating vascular endothelial 
cells to release proangiogenic cytokines.37  
Countering the above mechanisms, neutrophils can also have an opposing function 
with regard to angiogenesis; it has been reported that neutrophils can be 
conditioned ex-vivo to release the anti-angiogenic isoform of VEGF (VEGF-A165b),38 
but it is yet to be proven if this occurs in-vivo. 
 
Immunomodulation 
As previously mentioned, neutrophils are known to express arginase. Arginase 
degrades arginine, an essential amino acid important in many cellular processes 
e.g. the proliferation of T cells. High arginase levels can be found in the tumour 
microenvironment and result in inhibition of T cell receptor expression and antigen-
specific responses, aiding tumour evasion.39 Neutrophils have been widely reported 
to suppress T cell proliferation in ex-vivo studies, with Coffelt et al. demonstrating 
this is inducible nitric oxide synthase (iNOS) dependent,40 but it must be noted that 
recently concerns have arisen about the accuracy of these assays when T cell 
activating microbeads have been used, as neutrophils can bind/ phagocytose the 
beads making them ineffective.41 Neutrophils have also been shown to induce the 
apoptosis of CD8 T cells in a TNF-a and nitric oxide (NO) dependent manner.42 In 
addition, neutrophils can suppress T cells via programmed death ligand 1 (PD-L1) in 
early-stage gastric cancers.43 Moreover, neutrophil depletion studies suggest that 
they may act to reduce the effectiveness of PD1 immunotherapy, in mouse 
models.44 Neutrophils recruit regulatory T cells into tumours via secretion of 
chemokine ligand 17 (CCL17), which may inhibit anti-tumour immunity.45 Finally 
neutrophils and pro-tumoural IL-17 gd T cells can conspire to promote metastasis.40 
Whilst there appears to be an ever-expanding list of ways in which neutrophils 
immunosuppress in the tumour microenvironment, nonetheless neutrophils can also 
be immunostimulatory and anti-tumour. Neutrophils can have a role in antigen 
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presentation,46 can stimulate T cell proliferation,47 and suppress pro-tumoural IL-17 
gd T cells via ROS.48 
These dichotomous immunosuppressive and immunostimulatory roles of neutrophils 
illustrate that their response is context specific, that there must be a degree of 
neutrophil plasticity, and that signals in the environment are of key importance. 
 
Extravasation and metastatic seeding 
Neutrophil extracellular traps (NETs) have been shown to sequester circulating 
tumour cells at distant sites and promote metastasis.49 This is also true in peritoneal 
fluid.50 Indeed, NETosis has been suggested as a biomarker predict patients as risk 
of metastasis in head and neck cancers.51 Beyond NETs, neutrophils also 
communicate with circulating tumour cells, driving cycle progression and increasing 
their metastatic potential.52 In addition, tumour cell extravasation into tissues is 
aided by interactions between b2 integrin on neutrophils and ICAM-1 on tumour 
cells, promoting anchoring to the vascular endothelium.53 Finally, tumour derived G-
CSF can initiate a pre-metastatic environment in distant organs, mobilising 
neutrophils from the bone marrow to swarm at the metastatic site before tumour 
cells arrive.54 
Conversely, Granot et al. showed that tumour entrained neutrophils (i.e. stimulated 
by the primary tumour) can inhibit metastatic seeding via hydrogen peroxide (H2O2) 
killing of disseminated tumour cells.55 It has recently been shown that H2O2 from 
neutrophils kills tumour cells by triggering a lethal influx of calcium via transient 
receptor potential cation channel subfamily M member 2 (TRPM2), an H2O2 
dependent calcium permeable channel expressed on cancer cells.56  
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1.2.4 Defining neutrophil populations: density, maturity, 
surface markers, morphology and anatomical site 
It is clear from earlier sections, that neutrophils display heterogeneity and plasticity 
of function in malignancy. But what other features define these neutrophils that are 
pro- or anti-tumour? The Eruslanov and Fridlender groups have carried out seminal 
work in the last few years where functional neutrophil subpopulations have been 
distinguished further by density, maturity, surface markers, morphology and 
anatomical site (Figure 1.3).46 47 57 59  
 
 
Figure 1.3: Neutrophil subpopulations defined by density, maturity, surface markers, 
morphology and anatomical site. 
The degree of crossover between LDN, N2 TAN and G-MDSC populations needs further 
delineation. LDN, low density neutrophils; NDN, normal (high) density neutrophils; TAN, 
tumour-associated neutrophils; G-MDSCs, granulocytic myeloid-derived suppressor cells.  
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Peripheral blood neutrophils 
Ex-vivo, neutrophils are commonly isolated from the blood by discontinuous density 
gradient. This results in the formation of a red cell pellet, a normal density 
(sometimes referred to as ‘high density’ in the literature) layer of cells and a low-
density layer of cells. Neutrophils are usually the predominant cell type in the normal 
density layer (normal density neutrophils, NDN) and peripheral blood mononuclear 
cells (PBMCs) are found in the low-density layer.60 In malignancy, there is an 
expanded population of neutrophils in the low-density layer (low density neutrophils, 
LDN), which can be further defined by maturity/morphology. LDN are large and are 
either immature with banded/ring nuclei, or mature with segmented nuclei. All low-
density neutrophils are pro-tumour, displaying immunosuppressive properties. NDN 
are small and mature with segmented nuclei and are anti-tumour. Of note, 
neutrophils from patients with malignancy resist apoptosis compared with healthy 
donor neutrophils. Finally, murine models showed LDN to originate from the bone 
morrow, but of interest TGF-b could also mediate the transition of NDN to LDN 
(displaying plasticity).58 59 
 
Human TAN 
In humans, TAN in early stage cancer are mature with segmented nuclei and are 
anti-tumour, activating T cell responses. Study of TAN from more advanced 
malignancies is proving more difficult, due to lack of availability of tissue to study 
(patients with advanced cancer do not typically undergo surgical resection).46 47 57 
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Neutrophil surface marker immunotyping (human) 
To date, it has proven difficult to distinguish between the neutrophil subpopulations 
described above, by surface marker immunotyping. Furthermore there have been 
difficulties when attempting to compare neutrophil subpopulations found in murine 
models to those found in humans.61 However, most groups use 
CD11b+CD15+CD66b+CD14- to identify neutrophils in humans. In addition, CD10 is 
proving to be a key marker for the maturation and suppressive potential of 
neutrophils. Indeed, going forward CD10 may reduce the need to use density 
gradients to define neutrophil populations.62 Of note, neutrophil maturity in cancer is 
an expanding field of interest, with Mackey et al. providing a good summary of the 
literature.63 
 
Myeloid-derived suppressor cells (MDSCs) and S100 proteins 
The name myeloid-derived suppressor cells, was originally coined over 10 years 
ago to describe a group of myeloid cells with immunoregulatory activity i.e. they 
suppress anti-tumour T cell functions (via arginase and ROS). Broadly speaking, 
they compose two phenotypical/morphological groups of cells: those similar to 
neutrophils (granulocytic/polymorphonuclear MDSCs or G-MDSCs/PMN-MDSCs) 
and those similar to monocytes (M-MDSCs). It is thought that during chronic 
inflammatory processes, such as malignancy, there is a persistent signal to recruit 
neutrophils and monocytes from the bone marrow (e.g. GM-CSF, G-CSF, M-CSF). 
As time goes on, the rate of demand on the bone marrow is such that these 
recruited cells are increasingly immature, and have aberrant function. These cells 
are MDSC, and as cancers progress they form a greater proportion of circulating 
cells. In humans as G-MDSCs and neutrophils can both be defined by the surface 
markers CD11b+CD14-CD15+(or CD66b+)CD33+ it has been difficult to distinguish 
between them. However, it is known that G-MDSCs are found in the low-density 
fraction of peripheral blood. Furthermore G-MDSCs express lectin-type oxidized 
LDL receptor 1 (LOX-1) and so this marker may be used to distinguish them, without 
the need for a density gradient.64 65  
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There has been interest in the S100 family of calcium binding proteins, as they are 
released during the inflammatory response to malignancy, and S100A8/A9 
(calprotectin) can act as a MDSC chemoattractant. In mouse models of malignancy, 
S100A8/A9 proteins have been shown to regulate the accumulation of MDSCs.66 
Indeed in models of colon cancer, MDSCs have been found to produce S100A8/A9, 
leading to an autocrine pathway for accumulation of MDSCs at metastatic sites, and 
furthermore, S100A8/A9 activated tumour cells promoting cancer progression.67 
There is debate as to how closely neutrophils and G-MDSCs are related.68 It seems 
increasingly likely that in humans, immature peripheral blood LDN and G-MDSCs 
are one and the same. However, mature peripheral blood LDN appear to be 
different to G-MDSCs. Furthermore, within tumours themselves the relationship 
between G-MDSCs and TAN is entirely unknown.69. Finally, using the name MDSC, 
that defines this group of cells based entirely on the single function of 
immunosuppression, is probably not that helpful, as it implies they only exist for this 
purpose, when in all likelihood they are more complex.17 70 
 
1.2.5 Tumour environment and neutrophil metabolism 
It is known that the tumour microenvironment has altered oxygen and metabolite 
availability. Oxygen sensing pathways and metabolic flux regulate neutrophil 
function and survival responses.71 72 Whilst neutrophils were traditionally viewed as 
purely glycolytic, there is Increasing interest in the metabolic plasticity of neutrophils 
in health and disease.73 It has become apparent that immature low-density 
neutrophils/ MDSCs utilise fatty acid oxidation. This enables them to circumvent 
nutritional limitations within their local tissue environment.74 In addition, uptake of 
fatty acids has been reported to contribute to their immunosuppressive activity in 
cancer,75 76 and facilitation of metastasis.77 Encouragingly, there evidence that 
Inhibition of fatty acid oxidation may be helpful in reducing this pro-tumour activity, 
and this could be an important therapeutic avenue in the future.78  
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1.2.6 Summary of neutrophil roles in cancer 
It is probably beneficial to move away from N1/ N2 terminology. N1/ N2 represent 
laboratory extremes of neutrophil function, whereas in reality there is likely to be a 
biological continuum/ spectrum of neutrophil actions. The overall pro- or anti-tumour 
behavior of neutrophils will be in flux, with neutrophils displaying plasticity 
dependent on their local tissue environment, and therefore having different roles at 
different sites. For cancers to progress, the overall balance will begin to tip in favour 
of immature pro-tumour neutrophils. This model is summarised in Figure 1.4, akin to 
the ‘macrophage wheel’ used by Pollard et al.27 The term G-MDSC is also too 
restrictive, defining a cell population based on a single feature. Appropriate 
neutrophil responses are dependent upon a functioning balance of bone marrow 
release, recruitment to sites of need, activation and appropriate action at target 
sites. G-MDSC and immature low-density neutrophils are likely to be one and the 
same population, reflecting a dysregulation of bone marrow neutrophil release, 
resulting in an expanded dysfunctional immature circulating neutrophil population, 
with detrimental actions when recruited to the target site.  
Figure 1.4 Mechanisms through which neutrophil subpopulations aid or abate 
tumourigenesis. 
The proportion of pro- and anti-tumour neutrophils at any one time is in flux, with a degree of 
plasticity and a spectrum of activity. However, for cancers to progress this balance must 
begin to favour immature pro-tumour neutrophils.   
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1.2.7 Areas of agreement and controversy 
Neutrophils are no longer seen as a simple first responder cell; they have complex 
multifaceted roles in all stages of malignancy with both pro- and anti-tumour roles. In 
cancer, neutrophils are a heterogeneous population and display plasticity. Several 
neutrophil subpopulations have been identified and are currently defined by a 
combination of features; density, maturity, surface markers, morphology and 
anatomical site. 
A recent review article by the Eruslanov group highlights the ongoing areas of 
controversy regarding the role of neutrophils in cancer.61 These mainly relate to 1) 
the limitations of translating murine tumour models to human pathology, and 2) the 
lack/quality of human data. These are addressed in turn, and examples given below. 
 
Limitations of translating murine tumour models to human pathology 
The most common form of murine model is transplantable tumours i.e. immortal cell 
lines that have undergone years of selective pressure and are chosen based on 
their ability to grow quickly when injected into the mouse. These tumours by 
definition have a very different natural history to the gradual evolution of a natural 
tumour, and therefore really only represent the later stages of malignancy. There are 
no shared neutrophil cellular markers between mouse and man. We do not know if 
immature LDN, G-MDSCs and N2 are the same cell population or not. N1/N2 
polarisation has not been shown in human TAN, and it seems more likely that in fact 
there will be a continuum of behaviour rather than these two extremes. Are N2 
neutrophils just immature cells recruited as a consequence of cancer and not a 
contributing cause? 
 
Quality of human data 
There is a lack of human tissue available from the later stages of cancer, as patients 
do not routinely have surgery. Furthermore, whilst peripheral blood may be more 
easily available from these patients (than solid tumour samples), the behavior of 
blood neutrophils may be completely different to that of TANs. When tumour 
samples are obtained, it must be noted that neutrophil function can be changed by 
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the process of disaggregation used to extract the neutrophils. Finally, in human 
studies, a lot has been attributed to ex-vivo T cell responses which may not reflect 
true physiology. For example, as previously described there are concerns about 




Overall, there needs to be an unpicking of the various neutrophil subpopulations, 
and a better understanding of their evolving roles as cancers progress, at both 
primary and metastatic sites. 
 
1.2.8 Neutrophils as therapeutic targets in cancer 
In terms of established therapies, neutrophils have been shown to be important 
players in the beneficial immune response to antibody-based cancer therapy,79 
photodynamic cancer therapy,80 and Bacillus Calmette-Guerin immunotherapy.81 
However, a growing area of research is considering neutrophils as a therapeutic 
target themselves. Whilst the short-lived nature of neutrophils and their essential 
role in host defense against infection will need to be considered, nevertheless, 
targeted therapies relating to neutrophil recruitment, function and polarisation may 
be an attractive add-on therapy to conventional treatments (i.e. 
chemotherapy/radiotherapy) and newer immunotherapies. For example, in terms of 
neutrophil recruitment, there is interest in targeting the CXCR2 pathway.82 Relating 
to neutrophil polarisation, there have been trials of TGF-b inhibitors as a cancer 
therapy.83 With regard to direct neutrophil-tumour interaction, there has been 
interest in the use of neutrophil elastase inhibitors.84  
Finally, an expanding area of interest is understanding how neutrophils respond to 
newer targeted cancer therapies. Inhibitors of the receptor Tyrosine kinase c-MET 
have been shown to inhibit neutrophil recruitment to tumours, with some concerned 
this may be detrimental,30 but others hopeful of benefit.85 As previously mentioned, 
neutrophils have been shown to express PD-L1, and therefore immune checkpoint 
inhibitors may have a role in reducing neutrophil suppression of T cell responses.  
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1.3 Lung cancer 
 
1.3.1  Initiation of lung cancer 
Around 7 out of 10 lung cancers are caused by smoking, which triggers genetic 
alterations in cells that can result in clonal proliferation.86 Lung tumours themselves 
are composed of a heterogeneous mix of clonally expanded subpopulations, with 
distinct molecular features. The most common genetic mutations in smokers are 
found in the Kirsten rat sarcoma (KRAS) and tumour protein p53 (TP53) genes. The 
most common mutations in non-smokers are found in the epidermal growth factor 
receptor (EGFR), receptor tyrosine kinase (ROS1) and anaplastic lymphoma kinase 
(ALK) genes.87 
 
1.3.2 Clinical classification, management and challenges 
Lung cancer is the third most common cancer in the UK. Around 87% of lung 
cancers are histologically non-small cell lung cancer (NSCLC). It is common for 
patients to have advanced (stage IV) disease at the time of diagnosis. When this is 
the case, less than 20% survive one year or more. Primary lung cancers are 
classified as either small-cell lung cancer (SCLC) or non-small cell lung cancer 
(NSCLC). NSCLC further divides into adenocarcinoma (most common), squamous 
cell carcinoma and large cell carcinoma (uncommon). The most common sites of 
metastasis in lung cancer are elsewhere in the lung, the pleura (usually resulting in 
pleural effusion), bone, brain, adrenal glands, liver and extrathoracic lymph nodes. 
Treatment options depend upon the stage of the cancer and the performance status 
(fitness) of the patient. The main therapies include surgery, chemotherapy, 
radiotherapy, targeted cancer drugs (e.g. tyrosine kinase inhibitors), immunotherapy 
(e.g. programmed cell death protein 1 inhibitors), or symptom control. Diagnosis is 
often made when the disease has already metastasised. Metastatic burden is the 
major driver of morbidity and mortality. There is a need for more effective treatments 
of metastatic disease, in addition to finding better ways to make diagnoses earlier.86 
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1.3.3 Modulation of the immune system in lung cancer: 
programmed death-ligand 1 (PD-L1) and programmed 
cell death protein 1 (PD1) 
T cells play a key role in host defence against cancer, by killing cancer cells. To 
carry out this function, T cells must become first become activated following antigen 
recognition. There are natural breaks (‘immune checkpoints’) for this immune 
response in order to prevent inappropriate T cell activity (e.g. autoimmunity): 
negative regulators of T cell activation include cytotoxic T lymphocyte antigen 4 
(CTLA4) and programmed death protein 1 (PD1).88 Cancers can express 
programmed death-ligand 1 (PD-L1 or B7-H1), which binds PD1, supressing T cell 
responses. Seminal work identified blockade of CTLA4,89 and PD1/PD-L1,90 as 
potential therapeutic targets, augmenting T cell responses to cancer. These 
discoveries have led to the clinical use of checkpoint inhibitors in lung cancer.  
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1.4 Summary and aims 
Appropriate neutrophil responses are dependent upon a functioning balance of 
neutrophil production, release from the bone marrow, recruitment to sites of need, 
activation and appropriate action at said sites, and effective clearance afterward. 
Dysregulation of this finely tuned homeostatic system results in disease.  
Neutrophils play an active role in cancer pathophysiology. They can be either pro- or 
anti-tumour, they form heterogeneous populations, and display plasticity. In cancer, 
neutrophil function appears to be dependent upon several factors including maturity 
and tissue microenvironment. Better understanding of these mechanisms may help 
to identify new immunomodulatory therapeutic targets. 
Whilst neutrophil populations have been described in early stage human lung cancer 
(predominantly anti-tumour role), and animal models have demonstrated their 
importance in both pre-metastatic and established metastatic sites (predominantly 
pro-tumour role), to date, there is limited data regarding human neutrophil 
populations in advanced lung cancer. There is the need for a greater understanding 
of the interplay between extrinsic cell signals and intrinsic cell features, in 
determining neutrophil roles in cancer, and the subsequent effects on tumour 
outcome. For example, it is known that neutrophils can be polarised to pro- or anti-
tumour phenotypes by environmental cytokines, but how neutrophil function is 
influenced by the extrinsic metastatic microenvironment in other ways, has not been 
fully delineated, nor how neutrophils interact with other immune cells and tumour 
cells at metastatic sites. In addition, there may be changes in the intrinsic features of 
neutrophils in cancer, that dictate their function.  
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This thesis aims to address the following questions: 
1. How does the NSCLC metastatic environment influence neutrophil function? 
2. What neutrophil populations are present in advanced NSCLC and do they 
have features specific to cancer? 
3. Are there intrinsic properties of neutrophil populations in advanced NSCLC 
that determine their function? 
This project utilises tissue from the NSCLC pleural metastatic site, as this provides a 
new and novel way of investigating neutrophil biology in the metastatic tumour 
microenvironment. The NSCLC pleural metastatic site is also routinely accessed 
clinically for diagnostic and therapeutic purposes, meaning tissue was frequently 
available for such work.
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Chapter 2 Methods 
 
2.1 Sample collection 
 
2.1.1 Ethical approvals 
Healthy donor participants were recruited from the University of Edinburgh Centre 
for Inflammation Research Blood Resource, ethical approval for which was granted 
by the Centre for Inflammation Research Blood Resource Management Committee. 
Study title: The Role of Inflammation in Human Immunity (AMREC 15-HV-013). 
Patient participants were recruited from NHS Lothian hospitals, ethical approval for 
which was granted by the NHS Lothian BioResource Tissue Governance 
Committee. Study title: Lung Cancer Characterisation to Develop Novel Molecular 
Stratification Imaging Probes for Lung Cancer (AMREC 15-ES-0094, SR419). 
 
2.1.2 Permitted sampling from patients 
Up to 500mL of pleural fluid was collected from patients undergoing diagnostic or 
therapeutic drainage of any pleural effusion as a routine part of their medical care. 
This tissue was surplus to diagnostic requirements and was taken from any excess 
that would otherwise have been discarded. An additional blood sample (up to 20mL) 
was taken concurrently. All patients gave written informed consent. 
 
2.1.3 Patient selection criteria and confirmation of diagnoses 
The shared exclusion criteria for all patients were: blood borne viruses, previous or 
current intravenous drug abuse, significant anaemia, steroid use or lack of capacity 
to give informed consent. 
The diagnosis of NSCLC was confirmed by the combination of positive histology and 
supporting radiological imaging. Specific exclusion criteria for NSCLC: active cancer 
therapy or having undergone cancer therapy in the last 12 months. 
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The diagnosis of parapneumonic effusion was confirmed by the combination of: 
blood tests suggestive of infection, supporting radiological imaging and the 
identification of an exudate by Light’s criteria (pleural fluid protein/ serum protein 
>0.5, or pleural fluid LDH/ serum LDH >0.6, or pleural fluid LDH >2/3rd of the serum 
LDH upper limit of normal). Specific exclusion criteria for pneumonia patients: known 
or suspected tuberculosis.  
 
2.1.4 Healthy donor selection criteria 
Healthy donors had to be fit and well. Exclusion criteria were: blood borne viruses, 
previous or current intravenous drug abuse, anaemia, blood clotting disorders, 
anticoagulant therapy, steroid use, under the age of 16 or infection in the last 2 
weeks. All healthy donors gave written informed consent. 
 
2.1.5 Blood collection method 
Blood was drawn using a 21-gauge butterfly needle directly into 10mL S-Monovete® 
sodium citrate tubes (Sarstedt), or alternatively into a syringe. If drawn by syringe, 
36mL of blood was immediately transferred into a 50mL polystyrene Falcon™ tube 
containing 4mL of 3.8% sodium citrate and mixed by gentle inversion. Samples were 
transported to the laboratory room temperature and processed within 2 hours. 
 
2.1.6 Pleural fluid collection method 
Pleural fluid was drawn by syringe and immediately transferred into polystyrene 
specimen containers. Samples were transported to the laboratory on ice and 
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2.2.3 Isolation of whole blood neutrophils (WBN) using 
EasySep™ enrichment kit 
For volumes of blood ³20mL, WBN were isolated using the EasySep™ human 
neutrophil enrichment kit (Stemcell). Of note this product has now been 
discontinued, and has been replaced by the EasySep™ human neutrophil isolation 
kit. The samples were first prepared by following the protocol outlined in section 
2.2.1, stopping at the point where the leukocytes were pelleted following dextran 
sedimentation. The leukocytes were counted using a C-Chip Neubauer 
haemocytometer, by taking an aliquot of the sample and staining with 3% acetic acid 
with methylene blue (Stemcell) to aid counting of nucleated cells (exclude any 
residual red cells).  
 
The EasySep™ human neutrophil enrichment kit was then used as per the 
manufacturer’s instructions. The leukocyte pellet was re-suspended in RoboSep™ 
buffer at a concentration of 5x107/ mL, and transferred into 5mL polystyrene round-
bottom tubes (maximum 2mL leukocyte suspension per tube). Isolation cocktail 
(tetrameric antibody complexes produced from mAb directed against CD2, CD3, 
CD9, CD19, CD36, CD56 and glycophorin A) was added at a concentration of 50µL/ 
mL of leukocyte suspension, the sample mixed, and then incubated at room 
temperature for 10 minutes. Nanoparticle beads were added at a concentration of 
100µL/ mL of leukocyte suspension, the sample mixed, and then incubated at room 
temperature for 10 minutes. The sample was topped up to a total volume of 2.5mL 
with RoboSep™ buffer, gently pipetted up and down 2-3 times and placed into an 
EasySep™ magnet (Stemcell) (without lid) for 5 minutes. Following this, the magnet 
and tube were together inverted in one continuous movement, the contents (isolated 
WBN) pouring out into a 15mL polystyrene Falcon™ tube. The isolated WBN were 
pooled, and washed with Gibco™ 1X DPBS prior to counting and use. WBN yield 
was typically ³1x106/ mL of blood donated (haemocytometer), with cell purity >99% 
(by morphology on cytocentrifuge slide). 
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Figure 2.2: CD66b staining of LDN populations isolated by three different methods. 
 
2.2.5 Isolation of whole blood neutrophils (WBN) and T cells 
from whole blood using EasySep™ direct kits 
For volumes of blood <20mL, WBN were isolated using the EasySep™ direct 
human neutrophil isolation kit (Stemcell). T cells were separately isolated using the 
EasySep™ direct human T cell isolation kit (Stemcell). Both kits had a similar 
protocol. Anticoagulated whole blood was transferred into 5mL polystyrene round-
bottom tubes (maximum 2.5mL per tube). The RapidSpheres™ were vortexed for 30 
seconds. Isolation cocktail was added at a concentration of 50µL/ mL of blood, 
followed by RapidSpheres™ at a concentration of 50µL/ mL of blood, the sample 
mixed, and then incubated at room temperature for 5 minutes. The sample was 
topped up to a total volume of 2.5mL (T cell kit) or 5mL (neutrophil kit) with 
RoboSep™ buffer, gently pipetted up and down 2-3 times and placed into an 
EasySep™ magnet (without lid) for 5 minutes. Following this, the magnet and tube 
were together inverted in one continuous movement, the enriched contents pouring 
out into a new 5mL polystyrene round-bottom tube. The same volume of 
RapidSpheres™ as used in the first steps was added to the new tube containing the 
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enriched cells, the sample mixed, and then incubated at room temperature for 5 
minutes. Next, the sample was placed into an EasySep™ magnet (without lid) for a 
further 5 minutes. Following this, the magnet and tube were together inverted in one 
continuous movement, the enriched contents pouring out into a 15mL polystyrene 
Falcon™ tube. The isolated cells were separately pooled, and washed with Gibco™ 
1X DPBS prior to counting and use (centrifugation at 320G for 6 minutes 
(acceleration 9, deceleration 5)). Neutrophil yield was typically ³1x106/ mL of blood 
donated. T cell yield was typically ³0.5x106/ mL of blood donated (haemocytometer). 
Cell purity was >99% (by morphology on cytocentrifuge slide). 
 
2.2.6 Processing of pleural fluid 
Pleural fluid was processed immediately following collection. The sample was 
poured through 100µm Fisherbrand™ cell strainers (ThermoFisher) into 50mL 
polystyrene Falcon™ tubes, then centrifuged at 400G for 10 minutes at 4°C 
(acceleration 9, deceleration 9). The supernatant was removed, poured through 
40µm Fisherbrand™ cell strainers (ThermoFisher) into 50mL polystyrene Falcon™ 
tubes, sterile-filtered using Millex®-GP 0.22µm polyethersulfone syringe filters 
(Sigma-Aldrich), aliquoted, flash frozen and stored at -80°C for future use (pleural 
fluid supernatant (PFS)). The cell pellets were pooled into an appropriate number of 
50mL polystyrene Falcon™ tubes and re-pelleted prior to hypotonic red cell lysis. 
For red cell lysis, the cell pellet was re-suspended in 20mL of buffer A (0.2g NaCl in 
100mL sterile water), the Falcon™ tube inverted ten times, 20mL of buffer B added 
(1.6g NaCl and 0.1g dextrose in 100mL sterile water), the Falcon™ tube inverted, 
then centrifuged at 350G for 6 minutes (acceleration 9, deceleration 5). The cells 
were then washed with Gibco™ 1X DPBS prior to use (centrifuged at 300G for 6 
minutes (acceleration 9, deceleration 9). The leukocytes were counted using a C-
Chip Neubauer haemocytometer, by taking an aliquot of the sample and staining 
with 3% acetic acid with methylene blue to aid counting of nucleated cells (exclude 
any residual red cells). Cytocentrifuge slides of the leukocyte suspension were also 
made. 
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2.2.7 Optimisation of pleural fluid neutrophil (PFN) isolation 
Six different methods (a-f) were investigated, to find which provided the purest PFN 
population from the pleural fluid leukocyte population (isolated as per 2.2.6), with 
acceptable cell yield: 
a. Discontinuous Percoll™ density gradient (73%/ 61%/ 49%, Table 2.2) (the 
same as that used for blood samples, see gradient section of 2.2.1). The 
gradient was constructed with 3mL in each layer, with the cells re-suspended 
in 49% Percoll™ at the top. This was centrifuged at 720G for 20 minutes 
(acceleration 1, deceleration 0). Neutrophils were expected to be found at 
the 61%/ 73% interface post centrifugation. 
b. Discontinuous Percoll™ density gradient (78%/ 69%/ 52%, Table 2.4) (the 
same as that used for Broncho Alveolar lavage samples). The gradient was 
constructed with 3mL in each layer, with the cells re-suspended in 52% 
Percoll™ at the top. This was centrifuged at 1200G for 30 minutes 
(acceleration 1, deceleration 0). Neutrophils were expected to be found at 
the 69%/ 78% interface post centrifugation. 
c. 4 layer discontinuous Percoll™ density gradient (54%/ 45%/ 36%/ 27%, 
Table 2.4) (as per Hamburger et al.92). The gradient was constructed with 
3mL in each layer, except the top layer, which consisted of the cells re-
suspended in 1mL of 27%. This was centrifuged at 800G for 30 minutes 
(acceleration 1, deceleration 0). Neutrophils were expected to be found in 
the cell pellet at the bottom of the gradient post centrifugation. 
d. Ficoll-Paque PLUS™ (GE Healthcare) density gradient (as per Aleman et 
al.93). The gradient was constructed with 5mL Ficoll-Paque PLUS™ as a 
bottom layer, with the cells re-suspended in 5mL Gibco™ RPMI 1640 
medium (ThermoFisher) on top. This was centrifuged at 840G for 20 minutes 
(acceleration 9, deceleration 0). Neutrophils were expected to be found in 
the cell pellet at the bottom of the gradient post centrifugation. 
e. EasySep™ human neutrophil enrichment kit (in a similar fashion to the 
second part of 2.2.3). 
f. Fluorescence-activated cell sorting (as per 2.2.8).  
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Figure 2.3: CD66b staining of PFN populations isolated by two different methods.  
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2.2.8 Isolation of highly pure pleural fluid neutrophils (PFN) 
by fluorescence-activated cell sorting 
Pleural fluid leukocytes prepared as per 2.2.6 were pelleted and re-suspended in 
Gibco™ 1X DPBS (without FBS) at a concentration of 5x107/ mL, then a maximum 
of 3mL transferred into a 5mL polystyrene round-bottom tube. Antibodies to CD3 
and CD14 (BioLegend, Table 2.6) were each added at a concentration of 1µL/ 1x106 
leukocytes and the sample incubated for 30 minutes at 4-8°C protected from light. 
DAPI (ThermoFisher) at a working concentration of 100µg/ mL was added at 1:1000 
(final concentration 0.1µg/ mL), immediately prior to fluorescence-activated cell 
sorting using the BD FACSAria™ Fusion flow cytometer running BD FACSDiva™ 
software version 8.0 (BectonDickinson). The gating strategy used is outlined in 
Figure 2.5. The cytometer was fitted with a 70µm nozzle. Samples were collected 
into 200µL of Gibco™ 1X DPBS (without FBS) in a 15mL polystyrene Falcon™ 
tube, with a maximum sorting time of 3 hours. The isolated neutrophils were washed 
with Gibco™ 1X DPBS, prior to counting (haemocytometer) and downstream use. 
This method provided neutrophils of a high purity (Table 2.5 and Figure 2.4). 
 
Antigen Fluorophore Clone Source Product code 
CD3 PE HIT3a BioLegend 300308 
CD14 AF700 63D3 BioLegend 367114 
Table 2.6: Antibodies used for fluorescence-activated cell sorting.  
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2.3 Cell culture conditions 
 
2.3.1 Various media conditions 
Glucose-free media: this was used for glucose-free cell culture experiments. It 
consisted of Gibco™ RPMI 1640 no glucose medium (2mM L-glutamine) 
(ThermoFisher), supplemented with 1% Gibco™ Penicillin-Streptomycin 
(ThermoFisher) and 10% Gibco™ dialysed FBS (ThermoFisher). 
Glucose replete media: this was the standard media used for most cell culture 
experiments. It consisted of Gibco™ RPMI 1640 medium (2mM L-glutamine and 
11mM D-glucose), supplemented with 1% Gibco™ Penicillin-Streptomycin and 10% 
FBS (PAN-Biotech) (or instead 10% Gibco™ dialysed FBS when for an experiment 
also including glucose-free conditions). 
Media supplemented with pleural fluid supernatant (PFS): PFS was extracted as per 
2.2.6. This was defrosted in a water bath at 37°C. Glucose-free media or glucose 
replete media was supplemented with 10% PFS, unless otherwise stated. 
 
2.3.2 Normoxia (12kPa O2) vs. hypoxia (4kPa O2) 
Normoxic cell culture (the standard condition unless otherwise stated) was carried 
out in a ThermoFisher Heraeus BB15 CO2 incubator (O2 21%, CO2 5%, 37°C). 
Hypoxic cell culture was carried out in an Invivo2 400 hypoxic workstation 
(BakerRuskinn) (O2 1%, CO2 5%, 37°C). Culture media oxygen tension was 
confirmed by analysis using a RAPIDLab 348 blood gas system (Siemens). Mean 
PO2 of hypoxic media from 20 different samples was 4.4kPa (95% confidence 
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2.4.5 Neutrophil and T cell co-culture 
Neutrophils and T cells were isolated separately from whole blood (see 2.2.5). T 
cells were re-suspended in Gibco™ 1X DPBS (without FBS) at a concentration of 
1x106/ mL and labelled with 1:1000 Cell Tracker™ Green CMFDA dye (FITC-like) 
(ThermoFisher) at 37°C for 30 minutes protected from light. Following this the T 
cells were washed with Gibco™ 1X DPBS prior to use. The T cells were cultured in 
96 well Corning™ Costar™ plates, at a concentration of 1.5x105 per well (0.5x106/ 
mL of final culture media), in glucose replete media (see 2.3.1) with varying ratios of 
neutrophils. T cells were activated with Dynabeads™ human T-activator CD3/ CD28 
(ThermoFisher) at a ratio of 1:1 (round-bottom plate). Alternatively, T cells were 
activated with plate bound LEAF™ CD3 antibody (100µL per well of 1:200 dilution 
with Gibco™ 1X DPBS (without FBS) incubated overnight, then emptied out) and 
LEAF™ CD28 antibody (BioLegend) at 2µL/ mL of final culture media (flat-bottom 
plate). When a PD-L1 inhibitor was used (Human B7-H1 affinity purified polyclonal 
antibody (Bio-Techne)), this was at 10µg/ mL of final culture media. 
 
After 72 hours of culture, Dynabeads™ were removed with a magnet, the samples 
transferred to 5mL polystyrene round-bottom tubes, and washed with staining buffer 
(Gibco™ 1X DPBS supplemented with 2% FBS).  50µL of antibody master mix was 
added to each sample, then the samples incubated at 4-8°C for 20 minutes 
protected from light. Master mix consisted of staining buffer with antibodies at 
concentrations listed in Table 2.9. Samples were then washed and re-suspended in 
200µL staining buffer. DAPI at a working concentration of 100µg/ mL was added at 
1:1000 (final concentration 0.1µg/ mL), just prior to running each sample on the BD 
LSRFortessa™ cell analyser (BectonDickinson). UltraComp eBeads (ThermoFisher) 
stained with single antibodies were used to set up compensations. Unstained and 
fluorescence minus one controls were also used. BD FACSDiva™ software version 
8.0 was used for data acquisition of 10,000 ‘CD8+’. Data analysis was carried out 
using FlowJo 10.3 software (including the proliferation tool). The gating strategy and 
proliferation tool are demonstrated in Figure 2.9.   
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printed as 4 replicate spots on each sub-array (Figure 2.10). Array spotting was 
carried out with a 2470 Arrayer Platform (Aushon) using 185µm pins onto Oncyte 
Supernova 21x71mm slides (GraceBiolabs). Capture antibodies were printed at a 
concentration of 0.2mg/ mL in PBS supplemented with 0.05% Tween®20 (Sigma-
Aldrich). Detection antibodies were diluted 1:500 from stocks in PBS containing 
Tween, 5% bovine serum albumin and 10% SuperG™ blocking buffer 
(GraceBiolabs). 
Each slide (one per sample) was incubated with SuperBlock™ T20 (ThermoFisher) 
for 1 hour (all incubations and wash steps performed on a rocking platform). Each 
sample (1mL) was diluted with 2mL of PBS, making at total volume of 3mL that was 
incubated with a slide at 4°C overnight. A ‘background control’ slide using 3mL of 
PBS (containing no sample) was also created. Following overnight incubation, the 
slides were then washed three times for 5 minutes with PBS Tween, following which 
they were incubated with SuperG™ buffer for 10 minutes and then washed three 
times again with PBS Tween. The slides were clamped into the hybridisation 
cassette and incubated for 1 hour with detection antibodies (50µL per array). The 
slides were then washed three times for 5 minutes with PBS Tween, following which 
they were incubated with SuperG™ buffer for 10 minutes and then washed three 
times again with PBS Tween. They were then incubated for 30 minutes with 
Streptavidin 800 (Li-Cor) diluted 1:500 in PBS containing Tween, 5% bovine serum 
albumin and 10% SuperG™ blocking buffer. The slides were then washed three 
times for 5 minutes with PBS Tween, following which they were washed three times 
with PBS. After this they were washed with distilled water at room temperature, 
centrifuged for 5 minutes at 200G to dry, then air dried protected from light. 
Figure 2.10: Human cytokine microarray layout.  
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Microarray images (Figure 2.11) were analysed using Mapix software (Innopsys). 
The feature (spot) diameter of the grid was set to 270µm. Net signal per feature was 
calculated by subtracting the median background signal intensity (from the area 
adjacent to the feature) from the average feature signal intensity. Relative 
fluorescence intensity values were corrected by subtracting the values obtained 
from the ‘background control’ slide. The mean of the for replicates was then 
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2.5.3 ELISA 
DuoSet® ELISA sets, along with matching DuoSet® ancillary reagent kits, and as 
appropriate sample activation kits (TGFb only) (Bio-Techne), were used to quantify 
TNFa, GM-CSF, IFNb and TGFb in PFS. Each ELISA was carried out as per the 
manufacturer’s instructions, with PFS used undiluted.  
For the TGFb ELISA, the samples were activated immediately prior to the assay, by 
adding 20µL of 1 N HCl per 100µL of sample, mixing well, incubating for 10 minutes, 
then adding 20µL of 1.2 N NaOH/ 0.5 M HEPES per 100µL of sample to neutralise. 
100µL per well of this final mix was then used as the ‘sample’. 
96-well microplates were prepared by coating them in 100µL of diluted capture 
antibody per well, sealing and incubating overnight at room temperature. The plates 
were then washed three times with wash buffer (same for every wash) and then 
blocked with 300µL per well of reagent diluent at room temperature for 1 hour. 
Following this, the plates were washed again before adding 100µL of sample/ 
standards per well, sealing and incubating for 2 hours at room temperature. Of note, 
a seven-point standard curve was prepared by using two-fold serial dilutions in 
reagent diluent. After a further wash, 100µL of diluted detection antibody per well 
was added, the plate sealed with a new adhesive strip and incubated for 2 hours at 
room temperature. A further wash was performed, followed by the addition of 100µL 
per well of working dilution of Streptavidin-HRP. The plate was sealed and 
incubated for 20 minutes at room temperature, protected from light. The plates were 
washed, 100µL per well of substrate solution was then added and incubated for 20 
minutes at room temperature protected from light. 50µL of stop solution per well was 
then added and gently mixed. Optical density was then immediately determined 
using a BioTek Synergy™ HT microplate reader set to 450nm, using Gen5™ 
software (Agilent). Analysis of results was carried out using 
http://www.elisaanalysis.com, with four parameter logistic curve-fit.  
  Chapter 2 Methods 
  49 
2.6 Neutrophil phenotyping by flow cytometry 
 
2.6.1 Neutrophil subpopulation identification 
Following isolation (see 2.2), cells were re-suspended at a concentration of 1x107/ 
mL in staining buffer (Gibco™ 1X DPBS supplemented with 2% FBS). 100µL (1x106 
cells per sample) was transferred into 5mL polystyrene round-bottom tubes, and 
100µL of antibody master mix added. This was incubated at 4-8°C for 20 minutes 
protected from light. Master mix consisted of staining buffer with antibodies at 
concentrations listed in Table 2.10. Samples were then washed and re-suspended 
in 200µL staining buffer. DAPI at a working concentration of 100µg/ mL was added 
at 1:1000 (final concentration 0.1µg/ mL), just prior to running each sample on the 
BD LSRFortessa™ cell analyser. UltraComp eBeads stained with single antibodies 
were used to set up compensations. Unstained and fluorescence minus one controls 
were also used. BD FACSDiva™ software version 8.0 was used for data acquisition 
of 10,000 ‘Viable Cells’. Data analysis was carried out using FlowJo 10.3 software. 
The gating strategy used to identify CD66b+CD11b+CD15+CD14-CD49d- neutrophils 
is demonstrated in Figure 2.12.   
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Antigen Fluorophore Clone Concentration Source Product 
code 
CD11b PE Cy7 ICRF44 1:20 BioLegend 301322 
CD66b FITC G10F5 1:20 BioLegend 305104 
CD15 BV421 W6D3 1:100 BioLegend 323039 
CD14 AF700 63D3 1:20 BioLegend 367114 
CD49d PerCP Cy5.5 9F10 1:20 BioLegend 304312 
CD10 APC Cy7 HI10a 1:20 BioLegend 312212 
CD62L BV605 DREG-56 1:20 BioLegend 304834 
LOX-1 PE 15C4 1:20 BioLegend 358603 
Table 2.10: Antibodies used for neutrophil population phenotyping. 
 
2.6.2 Surface marker expression following PFS conditioning 
Isolated healthy donor neutrophils (see 2.2.1) were cultured at a concentration of 
5x106/ mL (7.5x105 neutrophils per well in 96 well Corning™ Costar ™ plates) in 
glucose replete media ± PFS (see 2.3.1), for 3 hours in normoxia. Following this, 
samples were transferred to 5mL polystyrene round-bottom tubes and washed with 
staining buffer (Gibco™ 1X DPBS supplemented with 2% FBS). 100µL of antibody 
master mix was added to each sample, then the samples incubated at 4-8°C for 20 
minutes protected from light. Master mix consisted of staining buffer with antibodies 
at concentrations listed in Table 2.11, or alternatively Table 2.12. Samples were 
then washed and re-suspended in 200µL staining buffer. Samples were run on the 
Attune™ NxT flow cytometer. Attune™ NxT software was used for data acquisition 
of 10,000 ‘Singlets’ (neutrophils first gated based on FSC/ SCC). Fluorescence 
minus one controls were used. Data analysis was carried out using FlowJo 10.3 
software.  
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Antigen Fluorophore Clone Concentration Source Product 
code 
PD-L1 PE 29E.2A3 1:20 BioLegend 329705 
Table 2.11: Antibodies used to assess PD-L1 expression. 
 
Antigen Fluorophore Clone Concentration Source Product 
code 
CD120a APC W15099A 1:20 BioLegend 369905 
CD120b PE 3G7A02 1:20 BioLegend 358403 
Table 2.12: Antibodies used to assess TNFa receptor expression. 
 
2.7 NanoString™ 
Transcriptomics is the study of RNA molecules within a cell. Messenger RNA 
indicates which genes are being actively expressed at that snap-shot in time. 
NanoString nCounter™ technology is a variation of a DNA microarray, that uses 
‘molecular barcodes’ and imaging to detect and count targeted transcripts in one 
hybridisation reaction (individual capture probes to targeted gene transcripts are 
labelled with a reporter probe that has a specific fluorescent barcode). Differentially 
expressed genes can be identified by comparing cell populations. 
 
2.7.1 Sample preparation 
Highly pure neutrophil populations were isolated (see 2.2.4 and 2.2.8). Aliquots of 
3x104 neutrophils were transferred into 1.5mL Eppendorf® tubes and pelleted (2000 
rpm for 6 minutes). The supernatant was removed, then each pellet re-suspended in 
6µL of 1/3 lysis buffer (1 part RLT (Qiagen) in 2 parts Ultrapure™ RNAse free 
distilled water (ThermoFisher)). This was pipetted up and down (to mix) 20 times 
without making bubbles. The resultant lysate was flash frozen and stored at -80°C 
for use in the assay. 
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2.7.2 Protocol 
The nCounter® human myeloid innate immunity panel (NanoString) was carried out 
by Alison Munro, at the Host and Tumour Profiling Unit (HTPU), Institute of Genetics 
and Molecular Medicine (IGMM), Edinburgh. NanoString™ was run according to the 
manufacturer’s protocols. 5µL of each sample lysate was used. Hybridisation was at 
65°C for 18 hours, ramped down to 4°C and held. The PrepStation was set at high 
sensitivity. The digital analyser was set at 555 fields of view (maximum resolution). 
 
2.7.3 Data analysis 
Raw data was processed using nSolver™ software version 4.0 (NanoString). All 
samples passed the in-built quality control measures. Data was then normalised, 
and a Log2 data matrix exported. Advanced analysis of this data matrix was then 
carried out with the help of Thomson Bioinformatics, Edinburgh (principal 
component analysis, heat maps, control boxplots, global Pearson correlations). Or 
Alternatively, using Excel (Microsoft) and Prism 8 (Graphpad) (differential 
expression). The DAVID 6.8 bioinformatics resource97 was used for functional 
annotation/ biological process over-representation analysis. 
 
2.8 Proteomics 
Proteomics is the study of all the proteins of a cell. To a degree this reflects the 
transcriptome, however protein quantity at a snap-shot in time is not just regulated 
by expression of the relevant gene, but also by its rate of degradation, post-
translational modification, etc. Proteins can then be considered in terms of their 
known interactions, cellular compartments and biological processes, using 
established databases. Differentially expressed proteins can be identified by 
comparing cell populations. 
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2.8.1 Neutrophil number determines the quantity of proteins 
that can be subsequently detected by proteomic 
analysis 
As it was planned to use smaller pellets of neutrophils for proteomics experiments 
than the group had used previously, an optimisation experiment was carried out to 
investigate the effect of smaller pellet sizes on protein yield. 
Neutrophils were extracted from healthy donor blood and matched pellets of three 
different sizes formed; 1.00x106, 0.50x106 and 0.25x106 neutrophils. Samples were 
processed (as per the methods section of this thesis), before undergoing single shot 
analysis, or alternatively were fractionated (8 fractions) prior to analysis. 
The total number of detected proteins decreased with smaller size neutrophil pellets 
both in single shot (Figure 2.13A) and fractionated (Figure 2.13B) samples. In 
addition, the number of detected proteins was approximately doubled to over 3500 
following fractionation (Figure 2.13B). Lower abundance proteins were the ones no 
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Iodoacetamide was then added as an alkylating agent, at a working concentration of 
20mM and the samples incubated at room temperature protected from light for 1 
hour. In-solution digestion was carried out using the SP3 beads protocol99 with 65µL 
digest buffer containing 1µg LysC (Promega) per 100µg protein, incubated overnight 
at 37°C shaking at 500rpm (Eppendorf® Thermomixer). Followed by 1µg Trypsin 
(Promega) per 100µg protein, incubated overnight at 37°C shaking at 500rpm. 
Peptides were eluted by adding 189µL of 2% DMSO in water and sonicating the 
samples for 5 minutes (cycles of 30 seconds on then 30 seconds off). Beads were 
removed with a magnet leaving a supernatant containing peptides. The supernatant 
was then centrifuged to remove non-magnetic bead debris.  
Peptides would then normally be quantified by CBQCA assay (ThermoFisher), to 
enable accurate dilution of samples to a concentration of 1µg per 15µL with 5% 
formic acid prior to single shot analysis. However, during optimisation experiments, 
the CBQCA assay was found to be redundant, due to the low levels of peptide 
obtained, making quantification inaccurate. Furthermore, fractionation yielded a 
much greater number of proteins compared with single shot analysis in optimisation 
experiments. Therefore, the CBQCA assay was not used, and to prepare samples 
for fractionation 21µL of 50% formic acid was added (to give a total volume of 210µL 
per sample, 5% working concentration of formic acid).  
Samples were subsequently fractionated using high pH reverse phase liquid 
chromatography. 200µL of sample was loaded onto a 2.1mmx150mm XBridge™ 
Peptide BEH C18 column with 3.5µm particles (Waters). Using a Dionex UltiMate™ 
3000 system (ThermoFisher), the samples were separated using a 25-minute 
multistep gradient, of buffers A (10mM ammonium formate at pH 9 in 2% 
acetonitrile) and B (10mM ammonium formate pH 9 in 80% acetonitrile), at a flow 
rate of 0.3mL per minute. Peptides were separated into 16 fractions which were 
consolidated into 8 fractions. Fractionated peptides were dried in vacuo then re-
suspended in 40µL of 5% formic acid for analysis by LC-ES-MS/MS. 
LC-ES-MS/MS was carried out at the Proteomics Facility, School of Life Sciences, 
University of Dundee. 15µL of each fraction was injected onto a Q Exactive™ Plus 
mass spectrometer (ThermoFisher). Samples were washed with 0.1% formic acid 
(10µL per minute) for 5 minutes prior to valve switch on an Acclaim™ PepMap™ 
100 nanoViper™ C18 trap column (100µm inner diameter, 2cm) (ThermoFisher). 
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2.8.4 Data analysis 
Raw data was processed using MaxQuant Software 1.6.2.6.100 101 The resultant 
protein groups data matrix was then imported into Perseus Software 1.6.2.3.102 In 
Perseus, several quality control measures were undertaken (removal of proteins 
only identified by site, reverse and potential contaminants), the proteins were 
functionally annotated and the data Log2 transformed. Pairwise comparisons were 
made between NSCLC neutrophil subpopulations and the healthy donor control 
group. To be included in analysis, a protein had to be present in a minimum of 3 out 
of 5 samples in one of the pairwise groups (i.e. control or NSCLC subpopulation). 
Imputation was then carried out to replace missing values (from a normal 
distribution). Where estimated copy numbers, concentrations and mass were 
required, these were added using the Perseus proteomic ruler plug-in. Perseus tools 
were also used to carry out principal component analysis and global Pearson 
correlations. Perseus matrices were then exported for further analysis using Excel 
and Prism 8 (e.g. differential expression). The DAVID 6.8 bioinformatics resource97 
was used for biological process over-representation analysis. Heatmaps were 
created using https://software.broadinstitute.org/morpheus. Network analysis was 
carried out using GeneMania.103  
 
2.9 Statistical analysis 
Statistical analysis was performed using Prism 8 or Excel. Data was assumed to 
follow a non-parametric distribution when sample size was insufficient to test for 
normality (n<8). Large data sets (Human cytokine array, NanoString™ and 
Proteomics) were normally distributed. When comparing two normally distributed 
groups, significance testing was performed using a t-test and summary data was 
expressed as mean ± SEM. When comparing two groups with non-parametric 
distribution, significance testing was performed using a Mann-Whitney/ Wilcoxon 
test and summary data was expressed as median ± interquartile range. Correlation 
of data was examined using Pearson’s test (normally distributed) or Spearman’s test 
(non-parametric). Results were considered significantly different when p<0.05.  
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In some experiments where >2 groups were being compared, Wilcoxon tests were 
used instead of a Friedman test e.g. when comparing any added effect of PFS 
versus no PFS (alternatively, glucose versus no glucose) in culture media, upon the 
apoptosis of healthy donor neutrophils in normoxia or hypoxia. This was because 
the ‘planned comparisons’ were within group (i.e. PFS versus no PFS in normoxia, 
PFS versus no PFS in hypoxia). It was already known that hypoxia has a survival 
advantage over normoxia. The primary aim was not to look at any other 
comparisons (of the 6 pairs available). Friedman with Dunn’s multiple comparisons 
was not chosen as it would test the null hypothesis ‘all groups means are the same’ 
and would therefore certainly have a p<0.05 (due to hypoxic survival). Dunn’s 
multiple comparisons would be too strict a test, as it would correct for all 6 
comparisons (when the ‘planned comparisons’ were only 2 of the 6 pairs), leading to 
an unacceptable chance of a Type II error. Using an uncorrected Dunn’s test for 
‘planned comparisons’ only would have been another option, but was less suitable 
to the question being asked than using Wilcoxon (as Dunn’s would be a post-hoc 
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Chapter 3 The NSCLC pleural environment 




3.1.1 Neutrophil function is modulated in response to the 
local environment, which is highly relevant at the 
metastatic site 
It is well known that metastatic tumour sites are often hypoxic, glucose deplete, and 
rich in cytokines.32 These features of the tumour microenvironment will have 
significant impact upon the function of recruited neutrophils. For example, key 
neutrophil functions such as phagocytosis and apoptosis are energy-dependent 
processes. Such microenvironmental features, have not yet been fully explored in 
human cancer models.  
 
Oxygen availability 
Oxygen sensing pathways regulate neutrophil function and survival 
responses.71 72 104 105 Hypoxia acts as a neutrophil survival signal.14 This is controlled 
by hypoxia-inducible factors (HIFs) and they in turn are regulated by prolyl 
hydroxylase domain enzymes (PHDs) and factor inhibiting HIF (FIH). In oxygen-
replete conditions PHDs hydroxylate the HIFa subunit. This targets it for 
proteosomal degradation by von Hippel-Lindau (VHL) protein, putting a halt to its 
downstream signalling. FIH can hydroxylate asparagine 803 on the HIFa subunit, 
preventing its binding to transcriptional co-factor p300/CBP. In hypoxia, the PHDs 
are inactive, HIFa binds HIFb and p300/CBP, and this complex activates hypoxia 
response elements (HREs) stimulating gene transcription (Figure 3.1 adapted from 
Watts et al.106). Neutrophil hypoxic survival is driven by HIF-1a-dependent NF-kB 
activity.71   
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Figure 3.1: The response to hypoxia is regulated by hypoxia-inducible factors (HIFs). 
In oxygen-replete conditions prolyl hydroxylase domain enzymes (PHDs) hydroxylate the 
HIFa subunit. This targets it for proteosomal degradation by von Hippel-Lindau (VHL) 
protein, putting a halt to its downstream signalling. In hypoxia, the PHDs are inactive, HIFa 
binds HIFb and p300/CBP, and this complex activates hypoxia response elements (HREs) 
stimulating gene transcription (adapted from Watts et al.106). 
 
Metabolic substrate availability 
Neutrophils contain few mitochondria and are traditionally viewed as being 
dependent upon glycolysis for their energy source. Hypoxia promotes glucose 
uptake and glycogen accumulation in neutrophils. When neutrophils are cultured in 
hypoxia, removal of glucose from the culture media or pharmacological inhibition of 
glycolysis, both result in loss of hypoxic survival.72  
There is now however increasing evidence that certain neutrophil populations refute 
this dogma, utilising other forms of metabolism. In murine models of cancer, tumour-
infiltrating granulocytic myeloid-derived suppressor cells (G-MDSCs), display 
increased fatty acid uptake and fatty acid oxidation.78 These G-MDSCs are thus able 
to circumvent nutritional limitations (i.e. low glucose) within their local tissue 
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environment, and through mitochondrial fatty acid oxidation are able to support 
immunosuppressive NADPH oxidase-dependent reactive oxygen species 
production.74 In addition, immunosuppressive activity of these cells may be 
mediated by fatty acid transport protein 2-dependent prostaglandin E2 synthesis.75 
Finally, in the absence of glucose, murine immature low density neutrophils (which 
are likely to be one and the same as G-MDSC) utilise glutamine and proline to 
support pro-metastatic NETosis.77 
 
Cytokines in the microenvironment 
Neutrophils can be polarised to pro- or anti-tumour phenotypes in response to 
cytokines within their microenvironment, such as TGFb and IFNb.25 26 58 Studies that 
emulate the tumour microenvironment in vitro by culturing neutrophils in media 
conditioned by cancer tissue or adding cytokines that are known to be present, have 
shown changes in neutrophil apoptosis and neutrophil-T cell interactions. However, 
such studies have been mainly limited to cancer cell lines or mouse models, and 
have been carried out with ex-vivo human tissue infrequently, e.g. from early stage 
lung cancer,46 47 early and late stage gastric cancer,43 107 and ovarian malignant 
ascites.108 What’s more, the mechanisms underlying these changes in neutrophil 
behaviour have not been fully decoded. 
 
3.1.2 Pleural effusion: a metastatic environment in NSCLC 
Mortality in patients with NSCLC most commonly relates to metastatic burden. It is 
therefore important to gain a better understanding of the mechanisms that permit 
metastatic tumour progression, and which features of the metastatic environment 
act as drivers. 
 
Pathophysiology and significance of pleural effusion in NSCLC 
In health, the pleural space between the visceral pleural membrane (outer lung 
lining) and parietal pleural membrane (inner chest wall lining) is filled by a <10mL of 
pleural fluid. This enables the lung to freely expand and contract with inspiration and 
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expiration, without friction. In advanced NSCLC patients can develop a much larger 
collection of pleural fluid (pleural effusion). The exact pathophysiological 
mechanisms underpinning this fluid accumulation are not fully understood, but there 
are thought to be three key factors. Firstly, there is increased permeability and leak 
from pleural membrane capillaries. Secondly, there is imbalance in oncotic and 
hydrostatic pressures between the vasculature and the pleural space. Thirdly, there 
is obstruction of lymphatic drainage. In advanced NSCLC, metastatic tumour 
deposits form on both pleural membranes, tumour cells float freely in the pleural 
fluid and there is an inflammatory response with infiltration of immune cells, 
including neutrophils, into the pleural space. All of these processes contribute to the 
three key factors already described.109 
The lung does not have any pain-sensing nerves; therefore, the first symptoms of 
NSCLC are often later in the disease process, with cough, haemoptysis, weight loss, 
shortness of breath or pain from metastatic sites (typically bone or liver). When 
pleural effusions become large, this causes compression of the underlying lung, 
leading to severe breathlessness. Therefore, for symptomatic relief, clinicians drain 
these effusions, also providing tissue from which a histological diagnosis may be 
made. Regrettably, NSCLC patients that first present to medical services with 
shortness of breath due to malignant pleural effusion, already have incurable stage 
IV disease with a median survival of around 3 months. 
 
Measurement of pleural fluid metabolites and cytokines is used to aid 
diagnosis and guide prognosis for pleural effusions 
NSCLC is the most common cause of malignant pleural effusion, but there are many 
other causes of pleural effusions (benign and malignant); examples are listed in 
Table 3.1. Historically, many studies looking into the components that make up 
pleural fluid (e.g. metabolites, cells and cytokines), have been carried out in order to 
help distinguish between said causes i.e. to aid diagnosis. Light et al.110 set out 
criteria based on pleural fluid protein and lactate dehydrogenase levels, that have 
been universally clinically accepted as the basis by which to define pleural effusions 
as either transudative or exudative. The gold standard test to confirm malignant 
pleural effusion is positive pleural fluid cytology for malignant cells.  
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Malignant pleural effusions have a reduced partial pressure of oxygen, and 
variable glucose levels 
Oxygen diffuses from the air into the blood stream, is transported around the body 
by haemoglobin in the blood and then disperses into tissues. Each of these steps 
has inherent inefficiencies; resultantly the partial pressure of oxygen drops 
significantly between the air and tissues (Figure 3.2). The partial pressure of oxygen 
in malignant pleural effusions has been measured to be 18-48% of that found in 
arterial blood,113 with a mean value of 3-5kPa.114-116 Malignant pleural effusions are 
oxygen deplete. Pleural fluid acidification and reduction in glucose in the acute 
setting is pathognomonic of infection/ empyema. However, pleural fluid pH and 
glucose can also fall in malignant pleural effusion over time.109 114 117 118 
Figure 3.2: The oxygen cascade. 
The partial pressure of oxygen reduces sequentially as the distance travelled from its source 
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There is the clinical potential to inject therapies into the pleural space, in 
order to modulate the malignant immune environment 
As the pleural space is easily accessible by needle when a pleural effusion is 
present, there has been the recognition that there is the potential to inject therapies 
into it. This has the benefit of making the treatment localised, limiting systemic side-
effects. Trials to date have focussed on modulating the malignant pleural immune 
environment, whether it be the introduction of genetically engineered T cells 
(chimeric antigen receptor T cells), inhibitor drugs or cytokines.119 Of note, there has 
been some success with IFNb gene transfer,120 a cytokine known to polarise 
neutrophils to an anti-tumour phenotype.26 
 
3.1.3 Summary 
Mortality in patients with NSCLC most commonly relates to metastatic burden. It is 
therefore important to gain a better understanding of the mechanisms that permit 
metastatic tumour progression, and which features of the metastatic environment 
act as drivers. Oxygen availability, metabolic substrate availability and cytokines in 
the microenvironment will determine neutrophil responses at the metastatic site in 
cancer. Pleural effusions are metastatic sites in NSCLC. They are low in oxygen and 
have variable glucose availability, and therefore share similarities with other 
metastatic sites. Pleural effusions are often drained for diagnostic or symptomatic 
purposes, providing tissue that can be used experimentally. Tissue from metastatic 
sites in human cancers has been infrequently used in the past due to lack of 
availability. Therefore, using NSCLC pleural fluid could provide novel insights into 
how the metastatic environment influences neutrophil function, with possible impacts 
on cancer outcome. Using pleural fluid from patients with pneumonia could also add 
information regarding the differences between cancer and non-cancer states. 
Finally, there is the potential that if new therapeutic targets were identified, drugs 
could be injected directly into the pleural space. 
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3.1.4 Hypotheses 
I hypothesised that the NSCLC pleural environment influences the function of 
neutrophils that have been recruited to this metastatic site, leading to an 
inappropriate and ineffective chronic inflammatory response to malignancy. I further 
hypothesised that the features of the NSCLC pleural environment would differ from 
those seen in pneumonia, an acute inflammatory condition that commonly, when 




To explore how NSCLC pleural fluid influences the function of neutrophils that have 
migrated to this space, and establish whether this results in a pro- or anti-tumour 
neutrophil behaviour. To elucidate the underlying mechanisms modulating the 
neutrophil immune response at this metastatic site in NSCLC. To define cancer-
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3.2.4 Glucose availability regulates neutrophil apoptosis 
To investigate the impact of glucose availability upon neutrophil apoptosis, blood 
neutrophils were cultured in media that was either glucose replete or glucose-free, 
with normal oxygen availability (21% O2 in atmosphere, 12kPa in media) or 
alternatively hypoxia (1% O2 in atmosphere, 4kPa in media). Apoptosis was 
measured at early (8-hour) and late (20-hour) time points. Apoptosis was quantified 
by cellular morphology (pyknotic nuclei) or by flow cytometry (positive Annexin V 
staining). 
At 20 hours, deprivation of glucose was found to have a diametric effect upon 
apoptosis, dependent on oxygen availability (Figure 3.6A and B). In normoxia, 
glucose deprivation was pro-survival (median 36.0% apoptosis versus 70.6% 
apoptosis, p=0.0312), whereas in hypoxia it was pro-apoptotic (median 84.5% 
apoptosis versus 42.5% apoptosis, p=0.0312) (also resulting in cell loss). This was 
seen in both healthy donor (Figure 3.6A and B) and NSCLC blood neutrophils 
(Figure 3.7). At the earlier time point of 8 hours (Figure 3.6C) glucose deprivation 
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3.2.6 NSCLC pleural fluid supernatant acts as a survival 
signal to neutrophils 
To study whether other signals within NSCLC pleural fluid supernatant itself (e.g. 
cytokines) condition neutrophil survival, healthy donor blood neutrophils were 
cultured in media supplemented with pleural fluid supernatant in normal oxygen 
availability or alternatively hypoxia. Apoptosis was quantified by cellular morphology 
(pyknotic nuclei) or by flow cytometry (positive Annexin V staining). 
In normoxia, NSCLC pleural fluid supernatant reduced the rate of apoptosis of 
healthy donor blood neutrophils at 20 hours. This effect was seen with 10% pleural 
fluid supernatant supplementation of culture media, with no added survival benefit of 
higher concentrations (median 29.9% apoptosis versus 60.0% apoptosis, p=0.0156) 
(Figure 3.9A). Pleural fluid supernatant was therefore used at a concentration of 
10% in all subsequent in vitro neutrophil functional assays investigating its role. In 
hypoxia, 10% pleural fluid supernatant did not have any additional added effect on 
the rate of apoptosis of healthy donor blood neutrophils (Figure 3.9B and C). 
A concern subsequently, was that NSCLC pleural fluid supernatant might induce 
healthy donor blood neutrophil necrosis/ cell loss, which was then not detected by 
the apoptosis quantification methods used, leading to a false result. Flow cytometry 
plots at 20 hours did not suggest this (Figure 3.10A and B), however to resolve this 
question, neutrophil counts were taken following 20 hours of culture with pleural fluid 
supernatant (Figure 3.10C). These counts were found to be identical to those taken 
following 20 hours culture without pleural fluid supernatant. 
A final supplementary investigation, was to assess whether NSCLC pleural fluid 
supernatant had any additional impact on the pro-survival signal of glucose 
deprivation in normoxia, which It did not (Figure 3.11).  
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Figure 3.10: NSCLC pleural fluid supernatant does not induce healthy donor normal-
density neutrophil necrosis/ cell loss. 
Representative flow cytometry plots of the 20-hour apoptosis of healthy donor normal-
density neutrophils cultured in normoxia in the absence (A) or presence (B) of NSCLC 
pleural fluid supernatant. (C) Neutrophil counts taken (Neubauer haemocytometer) following 
20 hours of cell culture ± 10% NSCLC pleural fluid supernatant (PFS), n=4 (each donor 
tested against two different pleural fluid supernatants). Analysed by Mann-Whitney test. 
Summary data represents median ± IQR.  
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3.2.7 NSCLC pleural fluid supernatant stimulates neutrophil 
phagocytosis of Zymosan A via opsonisation 
To consider whether NSCLC pleural fluid supernatant aided or abrogated the 
phagocytic capacity of neutrophils, healthy donor blood neutrophils were cultured in 
media supplemented with pleural fluid supernatant in normal oxygen availability or 
alternatively hypoxia. Phagocytosis was assessed by exposure to Zymosan A for 15 
minutes, and measured by cellular morphology. NSCLC pleural fluid supernatant 
increased the phagocytosis of healthy donor blood neutrophils (Figure 3.12A, C and 
D). However, it was thought this may be an opsonisation effect, which was 
supported when a similar result was obtained by adding non-autologous serum to 
the culture media (Figure 3.12B), p=0.8438.  
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3.2.8 NSCLC pleural fluid supernatant conditions neutrophils 
to inhibit CD8+ T cells via PD-L1 
To examine the impact of NSCLC pleural fluid supernatant upon interactions 
between the innate and adaptive immunity, a neutrophil-T cell co-culture was 
utilised. Healthy donor blood Cell Tracker Green™ labelled T cells stimulated with 
CD3/CD28, were cultured with varying ratios of healthy donor blood neutrophils in 
the presence or absence of 10% NSCLC pleural fluid supernatant. CD8+ T cell 
proliferation and activation was measured after 72 hours by flow cytometry (Cell 
Tracker Green and FlowJo proliferation tool, CD62L staining). NSCLC pleural fluid 
supernatant did not inhibit CD8+ T cell proliferation on its own, but did condition 
neutrophils to inhibit CD8+ T cell proliferation (median 7.6% proliferation versus 
43.9% proliferation, p=0.0286) (Figure 3.13A and B). Neutrophils conditioned by 
NSCLC pleural fluid supernatant also triggered a corresponding reduction in CD8+ T 
cell activation (median 13.5% activated versus 38.9% activated, although not 
statistically significant p=0.0571) (Figure 3.13C and D). In addition, the data in 
Figure 3.13 suggested that increasing ratios of neutrophils may inhibit CD8+ T cell 
proliferation on their own, even before the addition of pleural fluid supernatant 
(although not statistically significant). As there has been some concern in the 
literature that this may be an experimental artefact when Dynabeads™ are used for 
T cell stimulation,41 the experiment was repeated using plate bound LEAF™ 
antibody, confirming that this observation was not artefactual (Figure 3.14). 
Next, a mechanism to explain the T cell suppression by NSCLC pleural fluid 
supernatant-conditioned neutrophils was sought. Neutrophil surface expression of 
PD-L1 was found to be augmented by exposure to NSCLC pleural fluid supernatant 
(median fluorescence 1363 versus 873, p=0.0312) (Figure 3.15A and B). 
Furthermore, when the neutrophil-T cell co-culture was repeated with a PD-L1 
inhibitor (Figure 3.15C), there was partial reversal of the CD8+ T cell suppression 
(median 18.3% proliferation versus 3.9% proliferation, baseline 54.2%, p=0.0312).  
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Figure 3.15: NSCLC PFS conditions healthy donor neutrophils to inhibit CD8+ T cell 
proliferation via PD-L1. 
(A) Healthy donor neutrophils were cultured ± 10% NSCLC pleural fluid supernatant (PFS) 
(indicated by colour fill) for 3 hours, n=6. (B) Representative PD-L1 histogram of data shown 
in A. (C) CD8  T cell 72-hour proliferation measured in healthy donor cells stimulated with 
CD3/CD28 Dynabeads™ and cultured with or without heathy donor neutrophils (ratio 1:5) 
together with 10% NSCLC pleural fluid supernatant (indicated by bar colour fill) ± PD-L1 
inhibitor (indicated by triangle colour fill), n=6. Analysed by Wilcoxon test. Data represents 
individual values and median ± IQR (different donors, each tested against a different pleural 
fluid supernatant).  
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3.2.10 Neither pneumonia pleural fluid supernatant nor 
non-autologous serum act as a survival signal 
To affirm whether the pro-survival effect of NSCLC pleural fluid supernatant upon 
healthy donor blood neutrophils was NSCLC-specific, the apoptosis studies 
described in 3.2.6, were repeated using pneumonia pleural fluid supernatant or 
alternatively non-autologous serum. At the concentration of 10% in culture media, 
pneumonia pleural fluid supernatant did not change neutrophil apoptosis (Figure 
3.17A-C), and at higher concentrations it increased apoptosis (median 65.9% 
apoptosis versus 54.6% apoptosis, p=0.0373) (Figure 3.17A). Non-autologous 
serum had no impact upon healthy donor blood neutrophil apoptosis (Figure 3.18A 
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3.2.11 The pleural fluid supernatant cytokine profile in 
NSCLC differs to pneumonia, with N2 and pro-survival 
features 
To explore what signals in the pleural fluid supernatant may be responsible for 
manipulating neutrophil function, and to elucidate differences between NSCLC and 
pneumonia pleural fluid supernatant that may be of mechanistic importance in 
determining disease outcome, a human cytokine array was performed. This 
quantified the relative expression of 64 cytokines in NSCLC pleural fluid supernatant 
versus pneumonia pleural fluid supernatant (relative rather than absolute 
quantification). Despite significant heterogeneity between samples, clear patterns of 
differential expression were observed (Figure 3.19). Cytokines associated with 
immune tolerance, neutrophil survival and immune checkpoint (N2 features) were 
expressed at higher levels in NSCLC pleural fluid supernatant when compared with 
pneumonia pleural fluid supernatant (Figure 3.20). Cytokines associated with 
neutrophil chemotaxis and acute response (N1 features) were lower in NSCLC. In 
addition, TNFa was identified as a candidate neutrophil survival signal. When 
absolute quantification of TNFa was then subsequently measured in pleural fluid 
supernatant by ELISA, the levels in NSCLC were found to be higher than those in 
pneumonia (Figure 3.21).  
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Figure 3.19: Heat map showing relative expression of 64 pleural fluid supernatant 
cytokines in NSCLC versus pneumonia. 
The relative expression of 64 pleural fluid supernatant cytokines in NSCLC versus 
pneumonia was measured by human cytokine array (n=6 each group). Heat map colour 
shades based upon relative fluorescence intensity values.  
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3.2.12 The NSCLC pleural fluid supernatant neutrophil 
survival signal is TNFa 
Several experiments were carried out to cross-examine whether TNFa was indeed 
the NSCLC pleural fluid supernatant neutrophil survival signal. It is known that TNFa 
has a biphasic effect on neutrophil apoptosis, with a pro-apoptotic effect at earlier 
time points (via the CD120a) but an overall pro-survival effect at later time points 
(CD120b mediated).95 The healthy donor blood neutrophil experiments described in 
3.2.6 were therefore repeated with an earlier time point of 8 hours.  
These experiments demonstrated that the healthy donor blood neutrophil apoptosis 
response to NSCLC pleural fluid supernatant was indeed biphasic. Apoptosis of 
healthy donor blood neutrophils was increased at 8 hours, following exposure to 
pleural fluid supernatant (median 32.9% apoptosis versus 24.4% apoptosis, 
p=0.0182) (Figure 3.22A). Furthermore, the magnitude of the pro-apoptotic effect of 
NSCLC pleural fluid supernatant seen at the 8-hour time point, and the magnitude of 
the pro-survival effect of NSCLC pleural fluid supernatant seen at the 20-hour time 
point was proportional to the concentration of TNFa in the pleural fluid supernatant 
(Figure 3.22B and C) 
Next it was observed that NSCLC pleural fluid supernatant induced changes in 
healthy donor neutrophil TNFa surface receptor expression, favouring higher levels 
of the pro-survival receptor CD120b (median fluorescence 426 versus 362, 
p=0.0312) (Figure 3.23A-C). Finally, further evidence that the NSCLC pleural fluid 
supernatant neutrophil survival signal is TNFa came from using inhibitors of TNFa 
downstream signalling (Figure 3.24) and direct TNFa inhibitors, that reversed both 
the 8-hour (Figure 3.25A and B) and 20-hour (Figure 3.26A and B) healthy donor 
neutrophil NSCLC pleural fluid supernatant- induced apoptosis phenotypes.  
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Figure 3.23: NSCLC pleural fluid supernatant induces changes in healthy donor 
neutrophil TNFa surface receptor CD120b expression. 
Healthy donor neutrophils were cultured ± 10% NSCLC pleural fluid supernatant (PFS) 
(indicated by colour fill) for 3 hours, n=6. (A) CD120a surface expression. (B) CD120b 
surface expression. (C) Representative dot plots/ histograms. Analysed by Wilcoxon test. 
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3.3 Discussion 
 
3.3.1 NSCLC study population 
The NSCLC patients recruited to this study were representative of the wider 
population. They had features that would be expected, such as a significantly raised 
NLR and extensive smoking history. All patients included in analysis had positive 
histology for NSCLC. Only 1/3rd of patients received active treatment for their cancer 
(radiotherapy, chemotherapy or immunotherapy), which is typical for this group. 
Median survival of 73 days is slightly shorter than the 3 months that is widely 
anticipated, suggesting that this population may have had slightly more advanced 
disease. 
 
3.3.2 The metastatic environment impacts upon neutrophil 
function 
The data in this chapter confirms that there are several signals within the NSCLC 
pleural metastatic environment that influence neutrophil function. Key functions that 
are altered in this model include pro-survival and immunosuppressive neutrophil 
phenotypes. Hypoxia is a key driver of neutrophil survival, alongside TNFa 
signalling. As previously shown by our group, when neutrophils are cultured in 
hypoxia, removal of glucose from the culture media results in loss of hypoxic 
survival.72 This is a result of neutrophil dependency on glycolysis. However, of note, 
glucose is still available in the NSCLC metastatic site, which could be viewed as a 
surprising finding, considering the number of cells that would be expected to utilise 
glucose in this space. It would be interesting to explore in future work if glucose is in 
fact not being consumed by neutrophils in this setting (in contrast to pneumonia 
pleural fluid neutrophils), and whether other forms of metabolism e.g. fatty acid 
oxidation, are being used by neutrophils. Phagocytosis does not seem to be effected 
in this model of the pleural environment, which could aid anti-tumour responses, 
however this may not be the best measure of anti-tumour activity, as the mechanism 
by which neutrophils are most commonly described to be anti-tumour (in early 
cancers) is through cytotoxicity.55 121  
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3.3.3 TNFa modulates neutrophil apoptosis in advanced 
NSCLC 
TNFa is a well-known modulator of neutrophil apoptosis,13 with a biphasic response. 
TNFa is pro-apoptotic at early time points via CD120a (TNFR1) and pro-survival at 
later time points through CD120b (TNFR2).95 122 Pro-survival TNFa signalling is via 
PI3K-Akt-NF-kB and p38-MAPK pathways.96 123 TNFa is known to be present in 
early stage human NSCLC tumours,124 and is also present at metastatic sites (as is 
shown here in advanced NSCLC). The source of TNFa in NSCLC pleural fluid 
supernatant has not been established in this body of work; it can be released by 
multiple cell types including macrophages, T cells, eosinophils and neutrophils. It is 
therefore likely that there are multiple sources of TNFa in NSCLC pleural fluid 
supernatant.  
Of interest, it has been shown previously that chronic production of TNFa in the 
tumour microenvironment increases neutrophil recruitment, through IL-17 production 
by CD4+ T cells,125 CD8+ T cells can increase neutrophil survival in vitro via release 
of TNFa,126 and there is evidence that the TNFa p38-MAPK axis is important for 
neutrophil survival in head and neck cancers.127  
However, the data in this chapter provides novel insights into the role TNFa may be 
playing in sustaining neutrophilic inflammation at the NSCLC pleural metastatic site, 
with evidence derived by utilising NSCLC patient tissue, rather than cell lines or 
animal models.  The data shows that NSCLC pleural fluid supernatant makes 
neutrophils pro-survival and the response is proportional to the quantity of TNFa 
within the pleural fluid supernatant. Additionally, neutrophil surface expression of 
TNFa receptors is altered following exposure to pleural fluid supernatant. Finally, 
the pleural fluid supernatant- induced survival phenotype is reversed by TNFa 
pathway inhibitors. 
The data in this chapter also shows that NSCLC pleural fluid supernatant conditions 
neutrophils to inhibit CD8+ T cells via PD-L1. PD1/PD-L1 immune checkpoint 
inhibitors are used clinically to treat NSCLC; but this is based upon the fact that 
tumour cells have been shown to express PD-L1. Whilst it has been previously 
shown that neutrophils can be conditioned to express PD-L1 in human studies of 
gastric cancer43 107 and ovarian malignant ascites,108 this has never been shown 
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before in lung cancer. Of note, one study has demonstrated TNFa to induce 
neutrophil PD-L1 expression,128 however in this chapter when a TNFa inhibitor was 
used, the suppression of CD8+ T cell proliferation by neutrophils conditioned with 
pleural fluid supernatant was not reversed, suggesting that this is not a key 
mechanism here (although the expression of PD-L1 on neutrophils conditioned with 
pleural fluid supernatant in the presence of TNFa inhibitor was not measured, and 
could form a future experiment). The fact that a PD-L1 inhibitor did not completely 
reverse the phenotype either, raises the question of other mechanisms being 
involved in T cell suppression. Neutrophils have been described to inhibit T cells in 
many other ways, for example through release of proteases, reactive oxygen 
species and arginase.40 129 
The wider implications of the biphasic neutrophil apoptosis response in this setting 
requires further interrogation. For instance, it is not known whether TNFa is 
selecting out particular neutrophil populations for survival. For example, do older 
neutrophils undergo apoptosis in response to TNFa at the early time-point and 
younger neutrophils become pro-survival? 
The next question, is whether TNFa could be used as a therapeutic target. This is a 
complex issue, as TNFa-related neutrophil behaviour is context dependent.17 For 
example, in favour of TNFa inhibition would be evidence that tumour associated 
neutrophils induce T cell apoptosis via TNFa,42 and that transmembrane TNFa 
(precursor of the soluble form) promotes suppressive activities of MDSCs through 
CD120b.130 However in contrast to this, we also know that TNFa can induce tumour 
apoptosis,31 and mediates neutrophil cytotoxicity in breast cancer.131 Furthermore, in 
the context of malignant pleural effusion, the injection of intrapleural recombinant 
TNF may in fact be beneficial.132 Therefore more research is needed.   
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3.3.4 There are differences in the pleural environment in 
NSCLC compared with pneumonia 
The data in this chapter demonstrates that the NSCLC pleural environment differs 
significantly from that of pneumonia. Neutrophils do not gain a survival benefit 
following exposure to pneumonia pleural fluid supernatant, indicating that this 
phenotype is NSCLC specific. The human cytokine array and ELISA data suggest 
that the NSCLC environment, in contrast to pneumonia, would favour a phenotype 
of sustained and immunosuppressive inflammation. If this phenotype were to 
prevail, it would lead to an ineffective response in the face of progressing NSCLC 
metastasis. TGFb has commonly been noted to be raised in cancer 
microenvironments, and of note, in addition to its likely polarising effect upon 
neutrophils in NSCLC pleural fluid, it has previously been observed that TGFb 
derived from macrophages impairs T cells in malignant pleural effusion.133 
Reassuringly, many of the differences in cytokine profile seen between NSCLC 
pleural fluid supernatant and pneumonia pleural fluid supernatant fit with previous 
data. For example IL-8134 and MMP-9135 have previously been shown to be lower in 
malignant pleural effusions when compared with effusions secondary to infection. 
One striking difference on first inspection, when comparing the cytokine data shown 
in this chapter with previous data, is that many research groups have found TNFa to 
be lower in malignant pleural effusion than it is in effusions secondary to 
infection.136-139 This contradictory finding can however be explained by the case mix 
of patients in these other studies; they use pleural effusions from patients infected 
with tuberculosis. Tuberculosis is a chronic infection, with a very different immune 
profile and disease course, when compared with a standard bacterial pneumonia 
with parapneumonic effusion. In this study, tuberculous pleural effusions were 
excluded. It must be noted, that the previous studies were also looking for cytokine 
profiles that might distinguish tuberculous pleural effusions in particular, as they can 
be hard to confirm diagnostically.  
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3.3.5 Summary 
In summary, this chapter provides evidence that the NSCLC pleural environment 
conditions neutrophils into a state of persistent counterproductive inflammation 
(Figure 3.28). This is likely to permit cancer progression. TNFa and hypoxia act as 
pro-survival signals leading to neutrophil persistence. NSCLC pleural fluid conditions 
neutrophils to suppress CD8+ T cells through mechanisms that include PD-L1 
expression. Finally, the cytokine profile of the NSCLC environment differs 
significantly from that seen in pneumonia, and this leads to differences in neutrophil 
function e.g. apoptosis.  
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Figure 3.28: The NSCLC pleural environment conditions neutrophils into a state of 
persistent counterproductive inflammation. 
Summary of findings from this chapter. TNFa and hypoxia act as pro-survival signals leading 
to neutrophil persistence. NSCLC pleural fluid conditions neutrophils to suppress CD8  T 
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Chapter 4 There are cancer-specific neutrophil 
populations in advanced NSCLC 
 
4.1 Introduction 
Appropriate neutrophil responses are dependent upon a functioning balance of 
neutrophil production, release from the bone marrow, recruitment to sites of need, 
activation and appropriate action at target sites, and effective clearance afterward. 
Whilst neutrophils have been described to have anti-tumour function at the primary 
site in cancer, it appears they are detrimental at sites of metastasis. It is likely that 
dysregulation of the neutrophil homeostatic processes described above, contributes 
to cancer progression and worse outcome,17 however the mechanisms are not fully 
known. 
 
4.1.1 Immature neutrophil populations in cancer 
(dysregulation of bone marrow release/ recruitment) 
During times of acute inflammation e.g. infection, there is ‘left shift’ in the blood 
neutrophil population, with release of immature non-dividing cells into the 
circulation.4 Neutrophils are mobilised from the bone marrow by signals including 
granulocyte colony-stimulating factor, as part of the normal physiological response, 
and in this context usually have appropriate function, leading to timely resolution of 
the insult. In cancer, neutrophil recruitment signals become chronic, and the 
proportion of immature neutrophils in the circulation increases. These neutrophils 
are low-density and accumulate into a separate layer when blood is processed using 
a density gradient. Low-density immature blood neutrophils have nuclear 
morphology in keeping with the banded neutrophil stage of development, are long-
lived, and immunosuppressive. They are likely to be the same cell population as 
granulocytic myeloid-derived suppressor cells that have been described elsewhere. 
Mature low-density blood neutrophils are also found in cancer, the exact role of 
which needs to be further explored. Increasing proportions of the pro-tumour low-
density immature neutrophil population as cancers progress, will contribute to 
disease progression58 59  
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However, whilst there are many descriptions of low-density blood neutrophils in 
human cancers and animal models, there is a lack of data regarding how they relate 
to neutrophil populations found at the primary and metastatic cancer sites. The 
failure to identify distinguishing cell surface makers is often the given reason. 
 
4.1.2 Flow cytometry neutrophil markers in cancer 
As outlined above, distinguishing cell surface markers for immature low-density 
blood neutrophils/ granulocytic myeloid-derived suppressor cells are poorly defined. 
As these are considered to be immature cells recruited from the bone marrow, it is 
useful to consider granulopoiesis. Changes in surface markers during neutrophil 
development are outlined in Table 4.1 (created using data from two papers2 140). 
Useful markers of neutrophil maturity in mouse and man have also been recently 
well summarised by Mackey et al. and Hidalgo et al.2 63 
Of note, low levels of CD10 or CD16 are usually used to identify immature 
neutrophils in humans, and have been used to distinguish between mature and 
immature low-density blood neutrophils.62 CD66b and CD15 are typically used as 
neutrophil-specific markers, with some noting low-density blood neutrophils to have 
higher CD66b than normal-density blood neutrophils from the same patients.58 
CD14 is universally used to exclude monocytic cells. CD33 has been used 
previously for myeloid-derived suppressor cells, but does not distinguish them from 
neutrophils.64  
In terms of markers not mentioned in Table 4.1, shedding of CD62L is a marker of 
neutrophil activation and immature low-density blood neutrophils have been 
described as CD62L-.2  
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Table 4.1: Changes in surface marker expression during neutrophil development. 
CD66b and CD15 are typically used as neutrophil-specific markers. Levels of CD10 or CD16 
are used to identify immature neutrophils. CD14 is used to identify monocytic cells. CD33 
has been used previously to identify myeloid-derived suppressor cells (created using data 
from two papers2,140).   
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4.1.3 Lectin-type oxidised low-density lipoprotein receptor 1 
(LOX-1): a new marker  
Lectin-type oxidised low-density lipoprotein receptor 1 (LOX-1) is proving to be a 
useful marker of immature low-density blood neutrophils/ granulocytic myeloid-
derived suppressor cells. LOX-1 is a 50kDa transmembrane glycoprotein encoded 
by the OLR1 gene. It binds oxidised low-density lipoprotein. Expression is thought to 
be upregulated on the surface of immature low-density blood neutrophils/ 
granulocytic myeloid-derived suppressor cells by endoplasmic reticulum stress, and 
is associated with immunosuppressive activity of these cells.65 Uptake of 
lipoproteins could also provide the fuel source for fatty acid oxidation, which has 
been observed to be an important energy source for granulocytic myeloid-derived 
suppressor cells.78 Indeed low-density neutrophils may be low-density due to 
lipoprotein content. 
 
4.1.4 Neutrophil persistence in cancer 
It has been established for a long time that circulating neutrophils in patients with 
cancer have a long half-life (i.e. persist).141 This may be of key importance, as 
ineffective neutrophil clearance at the target site may lead to prolonged and 
detrimental inflammation, resulting in worse outcome.142 Many mechanisms can 
contribute to neutrophil apoptosis/death and clearance, and are described in the 
main introduction of this thesis. Neutrophil survival may be a result of extrinsic 
microenvironmental signals,13 but could also be a product of intrinsic programming. 
This has not been fully unpicked in cancer, nor have the apoptosis phenotypes of 
different neutrophil populations/ subpopulations been fully described in cancer.  
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4.1.5 Neutrophil function at metastatic sites (dysfunctional 
action at target sites) 
The understanding of neutrophil function at metastatic sites has improved greatly, 
but limitations to the data do remain. In terms of human studies, it is very difficult to 
obtain tissue from metastatic sites, as often it is not appropriate ethically. Therefore, 
most papers, alike the first results chapter of this thesis, have used circulating 
neutrophils, emulating the tumour/ metastatic site by culturing these cells with 
cytokines, or tumour-conditioned media.43 107 108 128 Whilst this has provided useful 
insights, attributing the functional outcomes of these cells to what happens at the 
metastatic site, must be done with caution. In rare cases where metastatic tumour 
has been obtained from patients e.g. lung metastases from breast cancer,143 studies 
of the whole tissue e.g. immunohistochemistry, tend to have been carried out. Whilst 
neutrophils have been extracted from primary human tumours for closer study,46 47 
this has not been done to date with metastatic tissue in humans. Mouse models 
have provided further insights. Indeed, the concept of neutrophils being important to 
metastasis has been proven by experiments where neutrophil recruitment was 
blocked or neutrophils were depleted.54 82 Of note, the predominant model used has 
been lung metastasis in breast cancer (4T1/ KEP). The 4T1 mammary carcinoma is 
a transplantable tumour cell line that is highly invasive and spontaneously 
metastasises to the mouse lung. The 4T1 model has shown immature neutrophils to 
be important in angiogenesis at the metastatic site and to supress interferon 
gamma.144 Building upon this work, type I interferon knock-out mice were shown to 
develop worse lung metastases.145 Furthermore, 4T1 breast cancer cells induce 
neutrophils to release neutrophil extracellular traps that promote metastasis.143 The 
KEP breast cancer model (a conditional model of invasive lobular breast cancer, 
K14cre;Cdh1F/F;Trp53F/F) was used to find that tumour produces Interleukin-1b, that 
stimulates pro-tumour gd T cells to express interleukin-17, leading to granulocyte 
colony-stimulating factor-dependent expansion and polarisation of immature 
neutrophils, that supress CD8 T cells via inducible nitric oxide synthase, permitting 
metastasis in the lung.146 Nonetheless, as in human studies, many of these animal 
studies use circulating or bone marrow neutrophils, rather than neutrophils from the 
metastatic site. Studies that extract neutrophils from metastatic tissue in animals are 
more infrequent, for example Wang et al. showed immature neutrophils from the 
pre-metastatic liver in a metastatic colorectal cancer model, stimulated tumour cell 
survival.147  
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4.1.6 Summary 
Whilst neutrophils have been phenotyped in several metastatic animal models, 
human data is limited. Studying neutrophils from the blood and pleural fluid 
(metastatic site) in advanced NSCLC, should provide novel insights into how the 
populations correlate across compartments, and their features. Comparing the 
populations to those found in pneumonia, will identify characteristics that are cancer-
specific, and that may have implications for disease outcome. Immature neutrophil 
populations are of key interest, and the markers CD66b, CD11b, CD15, CD10, 
CD62L and LOX-1+ may be of help in defining them further. To date, the balance of 




I hypothesised that there would be an expanded population of low-density immature 
blood neutrophils in advanced NSCLC, that would have an immunosuppressive 
phenotype. I further hypothesised that these low-density neutrophils would have 
distinct morphological appearances and expression of surface markers. Additionally, 
I hypothesised that there would be evidence for these neutrophils migrating into the 
pleural space, and that the neutrophil populations identified in NSCLC would have 
phenotypical differences from those found in other conditions e.g. pneumonia. 
 
4.1.8 Aims 
To identify and define the neutrophil populations present in the blood and pleural 
fluid of NSCLC patients; in terms of density, morphological appearances and flow 
cytometry surface marker expression. To find evidence that these NSCLC neutrophil 
populations are functionally distinct, with implications for disease outcome. To 
extract neutrophils from the pleural metastatic site for study.  
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4.2 Results 
 
4.2.1 Terminology used for neutrophil populations 
In this chapter, several neutrophil populations are described. The methods chapter 
of this thesis describes in full detail how each was harvested from samples. 
However, to aid interpretation of the results that follow, a brief overview is given 
below: 
Whole blood neutrophils (WBN) are blood neutrophils of all densities (not 
separated), and were obtained using EasySep™ kits. 
Normal-density neutrophils (NDN) are blood neutrophils, defined by the layer in 
which they resided following a discontinuous Percoll™ density gradient separation. 
Low-density neutrophils (LDN) are blood neutrophils, defined by the layer in which 
they resided following a discontinuous Percoll™ density gradient separation. 
Pleural fluid neutrophils (PFN) are neutrophils that were found in the pleural fluid, 
and when extracted, this was by fluorescence-activated cell sorting. 
Healthy donor neutrophils (HD) refers to blood neutrophils from healthy donors, 
harvested by matching method (EasySep™ kit and/or density gradient) 
 
4.2.2 Neutrophils are present in NSCLC pleural fluid 
To confirm that neutrophils were indeed present in NSCLC pleural fluid, cytospins of 
unprocessed pleural fluid were made (Figure 4.1A). Neutrophils were then identified 
by their typical morphology, with multi-lobed nuclei. Neutrophils were then quantified 
from pleural fluid by flow cytometry using cell markers CD66b+CD11b+CD15+CD14-
CD49d- and found to form 9% (mean) of pleural fluid leukocytes (Figure 4.1B).  
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4.2.3 There is an expanded population of low-density blood 
neutrophils in advanced NSCLC, that migrate into 
NSCLC pleural fluid 
In order to address whether an expanded population of low-density blood 
neutrophils was indeed present in NSCLC, blood leukocytes from NSCLC patients 
and healthy donors were each separated by discontinuous Percoll™ density 
gradient into normal-density neutrophil and peripheral blood mononuclear cell (low-
density) layers. Low-density neutrophils were identified in the peripheral blood 
mononuclear cell layer by flow cytometry using cell markers 
CD66b+CD11b+CD15+CD14-CD49d- and the quantity expressed as a percentage of 
the total layer (Figure 4.2). In health neutrophils formed <2% of cells, whereas in 
NSCLC neutrophils formed 11% (mean), p=0.0067. 
Next, the morphology of NSCLC low-density blood neutrophils was examined. 
NSCLC whole blood neutrophils were separated by discontinuous Percoll™ density 
gradient into normal-density and low-density neutrophils and cytospins made. When 
examining the morphological appearance of low-density neutrophils, the population 
was seen to consist a mixture of both immature banded and mature segmented cells 
(Figure 4.3A). In contrast, normal-density neutrophils were all mature in appearance. 
In addition, the magnitude of the low-density neutrophil population as a proportion of 
total neutrophils within the blood was determined by counting the number of 
neutrophils in the low-density layer (Neubauer haemocytometer) and dividing this by 
the sum of the number of neutrophils in the low- and normal-density layers. Low-
density neutrophils were found to form 9% (mean) of NSCLC whole blood 
neutrophils (Figure 4.3B). 
The cytospin morphology of NSCLC low-density blood neutrophils (Figure 4.4A) was 
compared with matched pleural fluid leukocytes (Figure 4.4B) to see if similar 
immature banded-nuclei neutrophils could be seen in both. This was indeed the 
case, providing some evidence that NSCLC low-density blood neutrophils migrate 
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4.2.4 Flow cytometry further defines a CD66bhigh neutrophil 
subpopulation in NSCLC 
To investigate whether NSCLC neutrophil populations could be further defined by 
surface marker expression, healthy donor blood neutrophils (HD) were compared 
with NSCLC normal-density blood neutrophils (NDN), NSCLC low-density blood 
neutrophils (LDN) and NSCLC pleural fluid neutrophils (PFN) by flow cytometry.  
A CD66bhighCD11b+CD15+CD14-CD49d- neutrophil subpopulation was identified by 
flow cytometry (for gating strategy, see Methods Figure 2.12), forming 13% (mean) 
of the NSCLC LDN population. It was also detected in the NSCLC PFN population, 
but was negligible in NSCLC NDN and HD (Figure 4.5A-D). 
The CD66bhighCD11b+CD15+CD14-CD49d- NSCLC LDN subpopulation was further 
examined by flow cytometry to see if there were any other surface markers that 
phenotypically distinguished it from the rest of the NSCLC LDN population 
(CD66b+CD11bhighCD15+CD14-CD49d- neutrophils). Expression of the maturity 
marker CD10 was lower in CD66high neutrophils than CD66b+ indicating that they are 
more immature (Figure 4.6A and B), p=0.0039. The activation marker CD62L was 
lower in CD66high neutrophils than CD66b+ indicating that they are more activated 
(Figure 4.6C and D), p<0.0001. Finally, CD66high neutrophils were also positive for 
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4.2.5 Neutrophil populations in pneumonia differ from NSCLC  
In order to interrogate whether the neutrophil populations found in NSCLC were 
unique to this disease state, the same set of phenotyping experiments was repeated 
with blood and pleural fluid neutrophils from patients with pneumonia. 
The proportion of neutrophils in the peripheral blood mononuclear cell (PBMC) (low-
density) layer of pneumonia patient blood was quantified by flow cytometry, again 
using cell markers CD66b+CD11b+CD15+CD14-CD49d-, and was revealed to be 
12% (Figure 4.7A). Whilst this was similar to that found in NSCLC (Figure 4.2), 
when the quantity of pneumonia low-density blood neutrophils was calculated as a 
proportion of pneumonia total blood neutrophils (Figure 4.7B), it was calculated to 
be 3%, which was 1/3rd of that seen in NSCLC (Figure 4.3B). 
The proportion of neutrophils in pneumonia pleural fluid was quantified by flow 
cytometry using the same cell markers. This was found to be 68% of pneumonia 
pleural fluid leukocytes (Figure 4.7C), around seven and a half times greater than 
observed in NSCLC (Figure 4.1B). 
Measured by flow cytometry, a CD66bhighCD11b+CD15+CD14-CD49d- subpopulation 
was present in pneumonia low-density blood neutrophils (Figure 4.7D). This 
subpopulation was not seen in the normal-density blood neutrophil population, in a 
similar manner to the observations in NSCLC (Figure 4.5A). However, in contrast to 
NSCLC, the CD66bhigh subpopulation was not detected in the pneumonia pleural 
fluid neutrophil population. 
Lastly, when the CD66bhigh and CD66b+ pneumonia low-density blood neutrophil 
subpopulations were further interrogated for expression of surface markers CD10 
(Figure 4.7E) and CD62L (Figure 4.7F), the data indicated that the CD66bhigh 
neutrophils were immature (CD10 low) and activated (CD62L low). This was similar 
to what was seen in NSCLC (Figure 4.6A and C). 
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4.2.6 NSCLC and pneumonia whole blood neutrophils have 
different apoptosis phenotypes 
Apoptosis was used as a functional readout by which to examine neutrophils from 
NSCLC and pneumonia. Whole blood neutrophils were extracted from NSCLC 
patients, pneumonia patients and healthy donors (HD). These neutrophils were then 
cultured in vitro for 20 hours, and apoptosis measured by cellular morphology 
(identified by pyknotic nuclei) or alternatively flow cytometry (positive Annexin V 
staining). 
Measured by flow cytometry, NSCLC whole blood neutrophils were pro-survival 
when compared with HD at 20 hours (median 33.2% apoptosis versus 51.5% 
apoptosis, p=0.0286) (Figure 4.8A-C). There was also an identical result when 
apoptosis was measured by cellular morphology (Figure 4.9A). In contrast, 
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4.2.7 All NSCLC neutrophil populations are pro-survival 
To determine if the pro-survival phenotype of NSCLC whole blood neutrophils was 
maintained in neutrophils that had migrated into the NSCLC pleural space, the 
apoptosis of NSCLC pleural fluid neutrophils was measured, and compared with that 
of healthy donor blood neutrophils. Furthermore, the apoptosis of NSCLC normal-
density and low-density blood neutrophils was examined to extrapolate if one or 
both contributed to the NSCLC whole blood neutrophil pro-survival phenotype. 
Isolated NSCLC and healthy donor neutrophil populations were cultured in vitro and 
apoptosis measured at 20-hours by flow cytometry (Annexin V staining). All NSCLC 
neutrophil populations had a survival advantage at 20 hours compared with healthy 
donor blood neutrophils (Figure 4.10A). 
Of note, when the 20-hour apoptosis flow cytometry dot plots of NSCLC neutrophil 
populations were examined (e.g. Figure 4.10B) it was noted that almost all NSCLC 
neutrophils that had entered apoptosis were at an early stage (TO-PRO-3 negative). 
Furthermore, it was noted in the NSCLC pleural environment chapter of this thesis 
that neutrophils in conditions modelling the NSCLC pleural environment became 
pro-survival via TNFa signalling, with upregulation of CD120b surface expression. 
The surface expression of CD120b was therefore measured by flow cytometry in all 
NSCLC neutrophil populations (Figure 4.10C). Surface expression of CD120b was 
higher in NSCLC low-density blood neutrophils and NSCLC pleural fluid neutrophils 
than that found in healthy donor blood neutrophils.  
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4.2.8 Not all environmental signals that impact upon healthy 
donor neutrophil survival impact upon NSCLC 
neutrophil survival at 20 hours 
In the NSCLC pleural environment chapter of this thesis, it was noted that NSCLC 
pleural fluid supernatant acted as a survival signal to healthy donor blood 
neutrophils. Hypoxia also acted as a survival signal to healthy donor blood 
neutrophils in glucose replete conditions, but when hypoxia was combined with 
glucose-free conditions, this resulted in cell death (of key importance to note, is that 
the pleural environment is NOT entirely glucose-free, but does have glucose levels 
lower than serum). 
To investigate whether the NSCLC pleural environment acts as an additional 
survival signal to NSCLC neutrophils that have migrated from the blood into the 
pleural space, NSCLC whole blood neutrophils were cultured in vitro with or without 
autologous pleural fluid supernatant in normoxia, or alternatively hypoxia (glucose 
replete media). Apoptosis was measured at 20 hours by morphological appearances 
(pyknotic nuclei). In normoxia there was no added survival effect of autologous 
pleural fluid supernatant (Figure 4.11A). In hypoxia, there was no added survival 
effect of autologous pleural fluid supernatant either (Figure 4.11B). For 
completeness, the NSCLC pleural fluid supernatants used in the above experiments 
were used for healthy donor whole blood neutrophil apoptosis cultures, confirming 
that despite not having an added survival effect on autologous NSCLC whole blood 
neutrophils, they were indeed survival signals for healthy donor whole blood 
neutrophils (Figure 4.11C). 
As was found with healthy donor blood neutrophils, NSCLC whole blood neutrophils 
had a reduced rate of apoptosis when exposed to hypoxia in glucose replete 
conditions (Figure 4.12A), but when hypoxia was combined with glucose-free 
conditions, this resulted in cell death (Figure 4.12B).  
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4.2.9 Apoptosis of pneumonia patient whole blood 
neutrophils is not reduced by autologous pleural fluid 
supernatant 
To investigate whether the pneumonia pleural environment acts as an additional 
survival signal to pneumonia patient neutrophils that have migrated from the blood 
into the pleural space, pneumonia patient whole blood neutrophils were cultured in 
vitro with or without autologous pleural fluid supernatant in normoxia (glucose 
replete media). Apoptosis was measured at 20 hours by morphological appearances 
(pyknotic nuclei). The rate of apoptosis was not reduced (Figure 4.13). 
 
 
Figure 4.13: Apoptosis of pneumonia patient whole blood neutrophils is not reduced 
by autologous pleural fluid supernatant. 
20-hour apoptosis of pneumonia patient whole blood neutrophils cultured with or without 
autologous pleural fluid supernatant in normoxia, n=3. Data analysed by Wilcoxon test. Data 
represents individual values (average of at least two replicates) and median ± IQR. Dotted 
shading indicates NSCLC neutrophils, darker bar colour fill indicates the presence of pleural 
fluid supernatant.  
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4.3 Discussion 
Neutrophils have been widely reported to be present in malignant pleural 
effusions,92 93 109 133 134 148-155 but whether they are able to carry out normal host 
defence functions, and the mechanistic role they may play in cancer 
pathophysiology at this metastatic site, have to date been largely neglected. 
Furthermore, whilst there has been some interest in the use of flow cytometry 
phenotyping to identify the different leukocyte populations in malignant pleural 
effusion,151 the data in this chapter provide more detailed insights into neutrophil 
populations, their function, and their correlations across the different cell 
compartments (i.e. blood versus pleural space) in advanced NSCLC.  
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4.3.1 Advanced NSCLC neutrophil population quantification 
Here it is reported that neutrophils form up to 21% (mean 9%) of pleural fluid 
leukocytes in NSCLC. This is in keeping with previous studies which have shown 
neutrophils to form 12-31% (mean) of pleural fluid leukocytes in malignant pleural 
effusion.133 134 149 152 Indeed, it is typical for neutrophils to  constitute <25% of this cell 
population.109 However, whilst neutrophils form a minority cell population in 
malignant pleural effusion, it is key to note that as their proportion increases, patient 
prognosis worsens.153 
Next the data in this chapter confirms the presence of low-density neutrophils in the 
blood of advanced NSCLC patients. This is a population that is present at negligible 
levels in health. Advanced NSCLC low-density neutrophils were quantified as 
forming 11% (mean) of the peripheral blood mononuclear cell layer (low-density 
layer) and 9% (mean) of total blood neutrophils. This is similar to what has been 
found previously; Liu et al. studied the blood of patients with stage III and IV lung 
cancer and found an increased ratio of low-density to high-density neutrophils 
compared with healthy donors, and Sagiv et al. studied blood from patients with lung 
or breast cancer (stage not specified), reporting low-density neutrophils to form 19% 
of the low-density blood fraction and 4% of total blood neutrophils.58 156 In addition, 
G-MDSCs have been described to constitute 9% of immune cells in stage III-IV lung 
cancer, with increasing levels correlating with worse overall survival.157  
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4.3.2 Defining advanced NSCLC neutrophil subpopulations 
by morphology and flow cytometry 
In terms of cellular morphology, this chapter describes NSCLC low-density blood 
neutrophils to be a mixed population of both mature cells (segmented nuclei) and 
immature cells (banded nuclei). These immature banded neutrophils could also be 
identified in pleural fluid. NSCLC low-density blood neutrophils were then further 
characterised, into two distinct subpopulations by flow cytometry phenotyping: 
1) CD66bhighCD11b+CD15+CD14-CD49d-CD10-CD62L-LOX-1+ immature cells 
2) CD66b+CD11bhighCD15+CD14-CD49d-CD10+CD62L+LOX-1- mature cells 
Concurrent CD66bhigh neutrophils were found in NSCLC pleural fluid, but were not 
present in the NSCLC normal-density blood neutrophil population nor in the blood of 
healthy donors. Marini et al. have previously demonstrated CD10- low-density blood 
neutrophils to have banded nuclei.62 This would therefore imply that the 
CD66bhighCD10- NSCLC low-density blood neutrophils identified here by flow 
cytometry, are indeed the banded nuclei neutrophils seen by cellular morphology, in 
both the NSCLC low-density blood and NSCLC pleural fluid populations. 
Nonetheless, it would be useful to carry out a fluorescence-activated cell sorting 
experiment to confirm this.  
LOX-1 was first described as a G-MDSC marker by Condamine et al., who found 
OLR1 to be upregulated in low-density blood neutrophils and surface expression of 
LOX-1 to match this, in a cancer patient population including patients with NSCLC.65 
These LOX-1+ neutrophils supressed T cells and were also identified in NSCLC 
primary tumours. This would suggest that the CD66bhighCD10- LOX-1+ NSCLC low-
density blood neutrophils identified in this chapter are G-MDSC, although T cell 
proliferation studies need to be carried out to prove this. 
Finally, the flow cytometry phenotyping data in this chapter builds upon previous 
work that identified two low-density blood neutrophil subpopulations by nuclear 
morphology in lung cancer patients. The study noted low-density blood neutrophils 
to have higher CD66b than normal-density blood neutrophils from the same 
patients, but did not define flow cytometry features by which to separate the low-
density blood neutrophil subpopulations.58  
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4.3.3 Neutrophil populations in advanced NSCLC are 
phenotypically and functionally different to pneumonia 
Aside from cancer, low-density blood neutrophils have also been studied in several 
non-cancer conditions including systemic lupus erythematosus,158 159 rheumatoid 
arthritis,160 asthma,161 psoriasis,162 HIV,163 severe infection,164 165 and tuberculosis.166 
However, the precise role low-density neutrophils play at target organs following 
migration is ongoing. It is also apparent that the pathophysiological function of low-
density neutrophils will vary between diseases. In this body of work, there was the 
wish to investigate how neutrophil populations in the blood and the end-target site 
(pleural space) may vary between NSCLC and pneumonia. Parapneumonic 
effusions represent an acute inflammatory response to infection, that usually 
spontaneously resolve. In contrast, NSCLC pleural effusions represent part of the 
chronic inflammatory response to metastatic malignancy, that is ineffective, with 
patients succumbing to metastatic disease burden. Differences in neutrophil 
populations may contribute to these divergent outcomes. 
The data in this chapter demonstrates that pneumonia neutrophil populations differ 
from NSCLC, with proportionally fewer low-density blood neutrophils and evidence 
that they either do not migrate into the pleural fluid in pneumonia, or that their 
phenotype alters during migration to that of a mature neutrophil. There were 
increased numbers of pleural fluid neutrophils in pneumonia compared with NSCLC, 
likely reflecting the acute inflammatory nature of pneumonia. It was also interesting 
to note that blood neutrophils in advanced NSCLC were pro-survival, whereas those 
in pneumonia were not. These key differences in low-density neutrophil populations 
and in neutrophil survival, could be of pathophysiological importance, which will 
need to be clarified in future work.  
A final and key consideration is that whilst immature low-density neutrophils appear 
to migrate into the pleural fluid of NSCLC (and do not do this in pneumonia), they 
still form a minority population when compared with normal-density neutrophils in 
this metastatic tumour microenvironment. Furthermore, in advanced NSCLC, pleural 
metastatic burden progresses over time. This raises the question of whether normal-
density neutrophils in this setting are simply ineffective, or whether the minority low-
density neutrophil population is having a significant detrimental effect upon whole 
neutrophil population responses at this metastatic site. This requires further 
investigation.  
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4.3.4 Evidence that neutrophil populations in advanced 
NSCLC are phenotypically and functionally different to 
early stage NSCLC neutrophil populations, and that the 
tumour microenvironments have opposing effects on 
neutrophil function 
It is helpful to make a point of comparing and contrasting the data shown in this 
chapter with that of the Eruslanov group.46 47 57 This group have extensively studied 
neutrophils in early human lung cancer (stage I-II NSCLC). Whilst there are some 
similarities in the data, there are some stark differences that will be of key 
importance in disease outcome. In short, whilst Eruslanov et al. show evidence that 
neutrophils are helpful at the primary site in early stage lung cancer, evidence in this 
chapter suggests the opposite is true at the metastatic site in advanced disease. 
Eruslanov et al. have shown that tumour-associated neutrophils from primary 
NSCLC tumours are NOT pro-survival in ex-vivo culture (80% 20-hour apoptosis) 
unless tumour-culture media at a concentration of 50% is added (40% 20-hour 
apoptosis). Furthermore, tumour-associated neutrophils had preserved 
phagocytosis, expressed low levels of PD-L1 and stimulated T cell proliferation.47 
The same group then went on to show that there is a tumour-associated neutrophil 
subpopulation with immature nuclei, originating from CD10- immature neutrophils, 
that stimulates and supports T cell responses. In addition, if they took mature human 
blood neutrophils and cultured them with tumour-culture media they died, but if they 
took immature human bone marrow neutrophils and conditioned them with tumour 
culture media, they lived longer and became like the tumour-associated neutrophil 
subpopulation i.e. in their surface markers and they stimulated T cells.46 
In contrast, the data in this chapter shows that neutrophils from the pleural 
metastatic site and populations from the blood in advanced NSCLC, were pro-
survival in ex-vivo culture, with increased expression of pro-survival TNFa receptor 
CD120b. The addition of autologous pleural fluid supernatant, akin to ‘tumour-
culture media’, had no added effect upon the survival of NSCLC whole blood 
neutrophils, counter to the findings in early NSCLC. Advanced NSCLC blood 
neutrophils had preserved phagocytosis, in a similar manner to tumour-associated 
neutrophils in early stage lung cancer. However, opposed to the findings in early 
stage NSCLC, neutrophil populations in advanced NSCLC all expressed high levels 
of PD-L1, suggesting an immunosuppressive role. The pleural fluid supernatant 
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studies found in the pleural environment chapter of this thesis also had contrary 
findings compared with the Eruslanov group studies in early NSCLC. Pleural fluid 
supernatant conditioned healthy donor blood neutrophils to live longer, express PD-
L1, and suppress T cells. 
 
4.3.5 Mechanisms underlying the neutrophil apoptosis 
phenotype in advanced NSCLC 
It is interesting to note in this chapter, that blood neutrophils in advanced NSCLC 
were pro-survival before they had even migrated to the pleural space. More than 
that, culturing blood neutrophils from NSCLC patients with autologous pleural 
supernatant had no additional survival benefit at 20 hours. This raises the question 
as to what the mechanism behind this was. 
Based on the pleural environment chapter of this thesis, it could be thought that the 
blood neutrophils in NSCLC are pro-survival due to TNFa signalling in the blood. 
However it has previously been shown that TNFa levels in NSCLC blood are not 
elevated.167 The same group, also showed that in stage III-IV NSCLC, normal-
density neutrophils expressed increased levels of CD47 and that this was 
associated with decreased levels of apoptosis.142 Of note, the intrinsic properties 
chapter of this thesis attempts to further address possible intrinsic mechanisms that 
may be behind this pro-survival NSCLC blood neutrophil phenotype. Indeed, it may 
be that in NSCLC there is functional imprinting of neutrophil bone marrow 
precursors, before they are even recruited to the blood.  
Another consideration, is that whilst autologous pleural fluid supernatant does not 
appear to have an additional survival benefit effect on NSCLC blood neutrophils at 
20 hours, it could act to sustain neutrophils at a later time-point. This could be 
investigated in future work. The Eruslanov group for instance, carried out neutrophil 
apoptosis studies following 7 days of culture with tumour-culture media.46 
TNFa signalling may also still be of importance to the survival of neutrophils in the 
pleural space. Not only does the data in the pleural environment chapter of this 
thesis and this chapter support this, but work from Aleman et al. does also.93 They 
showed that neutrophils from tuberculosis pleural effusions had a higher rate of 
apoptosis (although this was an immediate measure following fresh extraction, 
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rather than following 20 hours of culture) than neutrophils from malignant pleural 
effusions. Furthermore, the tuberculosis pleural effusion neutrophils had 
upregulation of CD120a (pro-apoptosis TNFa receptor) and phosphorylated p38 
kinase (pro-apoptosis). It would therefore be of interest in future work to measure 
20-hour apoptosis of parapneumonic effusion neutrophils and their CD120a/ 
CD120b/ phosphorylated p38 kinase expression. 
 
4.3.6 Summary 
The data from this chapter provides evidence for an expanded population of low-
density blood neutrophils in advanced NSCLC, that are not present in health, and 
that a proportion of which are immature with banded nuclei. A subpopulation of 
advanced NSCLC low-density neutrophils is CD66high, immature (CD10-), activated 
(CD62L-) and positive for a G-MDSC marker (LOX-1+). There is further evidence 
that these cells are also present in NSCLC pleural fluid, but in contrast these cells 
are not present in pneumonia pleural fluid. NSCLC pleural fluid neutrophils express 
PD-L1 and are long-lived with increased CD120b expression. Together this is 
suggestive that advanced (stage IV) NSCLC pleural fluid neutrophils may contribute 
to an environment of sustained inflammation that is ineffective in its response to 
increasing metastatic tumour burden. The advanced NSCLC neutrophil population 
features are summarised in Table 4.2. The findings of this chapter are the opposite 
of what has been described previously with regard to the role of neutrophils in 
primary tumours of early stage (I-II) NSCLC.46 47 57  
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Chapter 5 Intrinsic properties of neutrophil 
populations in advanced NSCLC 
define their function 
 
5.1 Introduction 
In this chapter, transcriptomics and proteomics are used in order to gain functional 
and mechanistic insight into advanced NSCLC neutrophil populations. Using these 
methods in tandem gives a large quantity of unbiased discovery-based data. 
Several studies have investigated the transcriptome of neutrophils in cancer, but 
none have done so with the purpose of correlating neutrophil populations in 
metastatic cancer across different cellular compartments in the same human donor, 
attempting to identify intrinsic mechanisms that may explain their function. To date, 
there have not been any publications regarding the proteome of human cancer 
neutrophil-specific populations. 
 
5.1.1 Mouse neutrophil transcriptomics in cancer 
Fridlender et al. carried out some of the earliest neutrophil transcriptomic work in 
cancer. They compared bone marrow neutrophils from mice without cancer, to 
immature spleen neutrophils from mice with flank tumours (lung cancer cell lines), 
and tumour neutrophils from mice with cancer. They found genes related to the 
respiratory burst were downregulated in the tumour neutrophils. Immature spleen 
neutrophils and tumour neutrophils upregulated antigen presenting genes and the 
genes for tumour necrosis factor and Interleukin-1. There was no significant 
difference in the apoptosis-related genes and pathways between the three 
populations. However, the anti-apoptotic members of the NF-kB family were 
upregulated in tumour neutrophils, and BH3 pro-apoptotic genes were upregulated 
in immature spleen neutrophils.168 Of note, a key limitation of this study was cell 
purity; above 85% neutrophil purity was the cut off (flow sorted cells from spleen and 
tumour samples). This may have led to transcriptomic data that over-represents 
antigen presenting capacity. They did not look at bone marrow neutrophils from 
mice with cancer. 
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The Fridlender group has been instrumental in showing that the cytokine TGFb can 
polarise mouse neutrophils to a pro-tumour phenotype.25 Shaul et al. from the same 
research group, used the identical mouse flank tumour model discussed above. The 
transcriptome of neutrophils isolated from the tumours of mice treated with a TGFb 
inhibitor (deemed anti-tumour neutrophils, N1) were compared with those from 
tumours of mice without inhibitor (deemed pro-tumour neutrophils, N2), and bone 
marrow neutrophils from non-tumour bearing mice. Antigen presentation genes were 
upregulated in N1 neutrophils. TNFa message expression and TNFR1 (pro-
apoptosis TNFa receptor) were upregulated in N1 compared with N2 neutrophils. 
Again, a key limitation of this study was cell purity; above 85% neutrophil purity was 
the cut off (flow sorted cells from tumour samples).169 
Finally, Zilionis et al. used single-cell RNA sequencing to demonstrate that tumour 
neutrophils exhibit phenotypes that are conserved between mouse and man in 
NSCLC. They analysed the transcriptome of early-stage human NSCLC blood and 
primary tumour immune cells, and compared them with tumour immune cells in 
NSCLC mouse models and immune cells in healthy mouse lung.170 
 
5.1.2 Human neutrophil transcriptomics in cancer 
Condamine et al. investigated the transcriptome of human cancer low-density blood 
neutrophils (referred to as granulocytic myeloid-derived suppressor cells in this 
study), from patients with NSCLC and head and neck cancer. These were compared 
with normal-density blood neutrophils from the same patients and healthy donor 
blood normal-density neutrophils. The primary aim of this study was to identify 
specific markers by which cancer low-density blood neutrophils could be 
distinguished from normal-density neutrophils.  
LOX-1 was identified as a cancer low-density blood neutrophil marker (transcription 
of its gene OLR1 was upregulated), and in subsequent assays 1/3rd of cancer low-
density blood neutrophils expressed LOX-1 on their cell surface. Flow sorting was 
used to isolate LOX-1+ and LOX-1- cells separately. LOX-1+ neutrophils had 
immature banded nuclei and suppressed T cells in culture. LOX-1- neutrophils had 
mature nuclei and did not suppress T cells in culture. 
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Normal-density blood neutrophils from healthy donors and cancer patients had 
similar transcriptomes. Cancer low-density blood neutrophils had upregulation of 
transcription of genes involved in translational initiation, the MAPK pathway and the 
NF-kB pathway.65 
 
5.1.3 Proteogenomic studies of neutrophil differentiation 
It is apparent that immature neutrophil populations are of key importance in cancer 
pathophysiology.63 Therefore it is pertinent to consider proteogenomic studies of 
neutrophil differentiation that have previously been carried out, in order to identify 
which bone marrow populations immature cancer neutrophils align to. The 
transcriptome of human bone marrow populations was described in detail by 
Theilgaard-Monch et al. demonstrating an elegant stepwise process of 
differentiation. As neutrophils differentiate they develop granules, loose proliferative 
capacity and become less pro-survival, and this is reflected in their gene 
transcription.171 Adding to this data, Rorvig et al. studied how the transcriptome and 
proteome of neutrophil granule proteins matches up during differentiation.172 
Complementary developmental analysis of murine bone marrow neutrophils has 
also been carried out.173 
 
5.1.4 Neutrophil granule development 
Transcriptomic and proteomic studies of neutrophils at various stages of 
development, have shown that neutrophil granules are produced at an immature 
stage of development in a controlled order.171 172 Primary granules are formed during 
the myeloblast to promyelocyte stage, secondary during myelocyte to 
metamyelocyte stage and tertiary from the band cell to segmented cell.17 The 
dogma is that mature neutrophils do not form new granules. Neutrophil granules, 
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5.1.6 Hypotheses 
NSCLC neutrophil populations would have distinct transcriptional and proteomic 
signatures. Intrinsic features and mechanisms would explain some of the functional 
phenotypes observed previously in this thesis e.g. apoptosis. The large quantity of 
unbiased discovery-based data would enable the identification of novel areas of 




To carry out transcriptomics and proteomics with NSCLC neutrophil populations and 
compare these with healthy control blood neutrophils. Identify novel mechanisms 
and key processes that may determine neutrophil behaviour and tumour responses 
at the metastatic site.  
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5.2 Results 
 
5.2.1 Terminology used for neutrophil populations 
In this chapter, several neutrophil populations are described. The methods chapter 
of this thesis describes in full detail how each was harvested from samples. 
However, to aid interpretation of the results that follow, a brief overview is given 
below: 
Normal-density neutrophils (NDN) are blood neutrophils, defined by the layer in 
which they resided following a discontinuous Percoll™ density gradient separation. 
Low-density neutrophils (LDN) are blood neutrophils, defined by the layer in which 
they resided following a discontinuous Percoll™ density gradient separation. 
Pleural fluid neutrophils (PFN) are neutrophils that were extracted from pleural fluid 
by fluorescence-activated cell sorting. 
Healthy donor control neutrophils (CTL) refers to blood neutrophils from healthy 
donors.  
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5.2.2 NSCLC neutrophil populations are transcriptionally 
distinct  
Through NanoString™ technology, the transcriptional behaviour of healthy donor 
control blood neutrophils (CTL) was compared with three NSCLC neutrophil 
populations; normal-density blood neutrophils (NDN), low-density blood neutrophils 
(LDN) and pleural fluid neutrophils (PFN). 
Principle component analysis (Figure 5.1), illustrated that although there was 
significant heterogeneity between samples, biological replicates from each 
population did cluster together. NDN clustered most closely to CTL and LDN 
clustered the furthest from CTL. 
Volcano plots of each NSCLC population versus CTL (Figure 5.2A-C), further 
demonstrated that LDN had the most differences compared with CTL, followed by 
PFN, with NDN the most similar to CTL. Tables of the statistically significant 
differentially expressed transcripts (LOG2 fold change >1 or <-1 and p<0.05) can be 
found in Appendix 1.  
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Figure 5.1: Principal component analysis of NanoString™ data. 
NSCLC neutrophil populations were compared with healthy donor control blood neutrophils 
through NanoString™ technology, n=3 biological replicates each group. CTL, healthy donor 
control neutrophils; NDN, normal-density neutrophils; LDN, low-density neutrophils; PFN, 
pleural fluid neutrophils.   
  
  Chapter 5 Intrinsic properties 
  157 
 
Figure 5.2: NSCLC neutrophil populations are transcriptionally distinct from healthy 
donor control blood neutrophils. 
NSCLC neutrophil populations were compared with healthy donor control blood neutrophils 
through NanoString™ technology, n=3 biological replicates each group. (A-C) Volcano plots; 
significantly upregulated (right) and downregulated (left) transcripts in NSCLC populations 
(number indicated, tables of transcripts can be found in Appendix 1) when compared with 
control. Analysed by t-test. Lines indicate LOG2 fold change >1 or <-1 and p<0.05. Data 
points represent individual gene transcripts. CTL, healthy donor control neutrophils; NDN, 
normal-density neutrophils; LDN, low-density neutrophils; PFN, pleural fluid neutrophils.    
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5.2.3 NanoString™ data supports flow cytometry surface 
marker phenotyping of NSCLC neutrophil populations 
It was sought to establish whether there was consistency between the flow 
cytometry surface marker phenotyping of NSCLC populations (found in the NSCLC 
neutrophil populations chapter of this thesis) and the transcription of genes coding 
for these markers. Transcription of genes coding for CD66b, CD62L and LOX-1 
were compared in NSCLC neutrophil populations (NDN, LDN and PFN) versus CTL 
(Figure 5.3A-C). 
In keeping with the flow cytometry surface marker phenotyping, LDN had 
significantly higher levels of transcription of the genes coding for CD66b (Figure 
5.3A) and LOX-1 (Figure 5.3C), and lower levels of transcription of the gene coding 
for CD62L (Figure 5.3B), when compared with CTL. Similar patterns of transcription 
were also seen in PFN when compared with control, with lower levels of 
transcription of the gene coding for CD62L (Figure 5.3B) reaching statistical 
significance. NDN were indistinguishable from CTL. 
Of note, the changes in the transcription of CD62L are modest, and must be 
interpreted with caution when correlated with CD62L surface marker expression 
measured by flow cytometry, as surface marker expression is likely to be influenced 
more by cell shedding of CD62L than by new CD62L protein production.   
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5.2.4 NSCLC low-density blood neutrophils have altered 
transcription of genes associated with apoptosis 
pathways and neutrophil granule production 
In order to interrogate how changes in the transcription of genes may impact upon 
neutrophil function in NSCLC, the DAVID 6.8 bioinformatics resource97 was used to 
carry out biological process over-representation analyses. 
Biological process over-representation analysis of NSCLC LDN downregulated gene 
transcripts versus CTL (LOG2 fold change<-1 and p<0.05), highlighted several key 
pathways relating to apoptosis (in bold, Table 5.2). Of particular interest was the 
TNF-mediated signalling pathway, due to evidence in the previous chapters of this 
thesis implicating its importance. A volcano plot highlighting significantly upregulated 
and downregulated TNF-mediated signalling pathway gene transcripts in NSCLC 
LDN versus CTL, revealed that pro-survival gene transcripts were upregulated, and 
pro-apoptosis gene transcripts were downregulated (Figure 5.4).  
Biological process over-representation analysis of NSCLC LDN upregulated gene 
transcripts versus control (LOG2 fold change>1 and p<0.05), indicated the term 
innate immune response (in bold, Table 5.3). On closer inspection, the gene 
transcripts that contributed to this finding were for genes coding neutrophil granule 
proteins. A Volcano plot highlighting neutrophil granule protein gene transcripts in 
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5.2.7 NSCLC neutrophil populations and healthy donor blood 
neutrophils have similar distributions of protein by 
abundance and mass 
The proteome of healthy donor control blood neutrophils (CTL) was compared with 
three NSCLC neutrophil populations; normal-density blood neutrophils (NDN), low-
density blood neutrophils (LDN) and pleural fluid neutrophils (PFN). Each sample 
was formed from 2.5x105 neutrophils. 
Before more detailed analysis of differential protein expression was undertaken, a 
global perspective of protein distribution within each neutrophil population was 
examined. Approximately 3500 proteins were identified in each population. All 
neutrophil populations had similar distributions of protein by abundance (Figure 
5.8A-D). The top 25 proteins by abundance were also similar in all populations 
(Figure 5.8E)  
Next, it was sought to establish if there was a difference between neutrophil 
populations in the distribution of proteins by mass (Figure 5.8F). The contribution of 
each protein to the total protein mass of each neutrophil population, was calculated 
using mean copy number and molecular mass for each of the identified proteins. 
The number of proteins contributing to each quartile of total protein mass of each 
neutrophil population was then calculated, along with the percentage they 
represented of total proteins identified in that same population. In all populations, 
around 5 proteins accounted for first 25% of total protein mass, and around 3400 
proteins accounted for the last 25% of total protein mass. 
Finally, to interrogate whether low-density neutrophils are such, as a result of 
differences in protein content, total protein mass was calculated using the proteomic 
ruler. LDN had a similar amount of total protein to CTL (Figure 5.8G).  
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5.2.8 NSCLC neutrophil populations have distinct proteomes 
with differential expression of proteins 
The proteome of healthy donor control blood neutrophils (CTL) was compared with 
three NSCLC neutrophil populations; normal-density blood neutrophils (NDN), low-
density blood neutrophils (LDN) and pleural fluid neutrophils (PFN). 
A heat map of Pearson’s correlations between samples, showed samples PFN4 and 
PFN5 to be outliers. After further investigation, one of these samples was found to 
have a very low amount of material and the other to be contaminated. Both were 
excluded from all subsequent analyses (Figure 5.9) 
Volcano plots illustrating significantly upregulated and downregulated proteins in 
each NSCLC neutrophil population when compared with CTL (Figure 5.10A-C), 
revealed NSCLC LDN to have the most differences. Tables of the statistically 
significant differentially expressed proteins (LOG2 fold change >1 or <-1 and 
p<0.05) can be found in Appendix 2.  
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Figure 5.9: Heat map of Pearson’s correlations between proteomic samples. 
The proteomes of all neutrophil populations were compared, n=5. Stronger correlations have 
a lighter colour. CTL, healthy donor control neutrophils; NDN, normal-density neutrophils; 
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Gene symbol Protein Role 
A2M Alpha-2-macroglobulin Protease inhibitor/ 
inflammatory cytokine inhibitor 
APOA1 Apolipoprotein A1 Promotes cholesterol efflux 
C3 Complement C3 Central role in activation of 
complement system 
C4B Complement C4B Classical complement 
pathway 
CAMK1D Calcium dependent protein 
kinase 1D 
Required for activation of 
respiratory burst 
CXCR1 C-X-C motif chemokine 
receptor 1 
Receptor for IL8 
OLR1 Oxidised low-density 
lipoprotein receptor 1 (LOX-1) 
Uptake of oxidised low-density 
lipoprotein 
ORM1 Orosomucoid 1 Modulates acute-phase 
response 
P2RX1 Purinergic receptor P2X 1 ATP-gated ion channel (linked 
to apoptosis) 
TNFAIP6 TNF alpha induced protein 6 Cell-cell interactions 
Table 5.5: NSCLC low-density blood neutrophil population downregulated 
inflammatory response proteins. 
(compared with healthy donor neutrophils). 
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5.2.10 NSCLC low-density blood neutrophils have 
increased translational initiation proteins/ ribosomal 
proteins 
Biological process over-representation analysis of NSCLC LDN upregulated proteins 
versus CTL (LOG2 fold change>1 and p<0.05), indicated the term translational 
initiation (in bold, Table 5.6). A volcano plot highlighting significantly upregulated 
and downregulated translational initiation proteins in NSCLC LDN versus CTL, 
revealed that most were upregulated (Figure 5.13A).   
Indeed, many eukaryotic translation initiation factor (EIF) proteins were upregulated 
in NSCLC LDN when compared with CTL (Figure 5.13B). There was statistically 
significant upregulation of subunits of EIF3 (subunits C, E, I and L) and EIF4 
(subunit E). During the initiation of transcription, EIF3 controls the assembly of the 
40S ribosomal subunit on mRNA, and EIF4 interacts with EIF3 and binds the 5’ cap 
structure of mRNA.  
Furthermore, when ribosomal proteins (identified by KEGG) were quantified as a 
proportion of neutrophil total protein, this was found to be upregulated in NSCLC 
LDN (Figure 5.14A). In fact, a wide range of both 40S ribosomal proteins (Figure 
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5.2.11 NSCLC low-density blood neutrophils have 
increased DNA replication proteins 
Network analysis of NSCLC LDN upregulated proteins versus CTL (LOG2 fold 
change>1 and p<0.05), was carried out using GeneMania.103 This demonstrated 
clustering of translational initiation proteins (orange) and also DNA replication 
proteins (green) (Figure 5.15). Indeed, biological process over-representation 
analysis had already indicated the term DNA replication (in bold, Table 5.6). DNA 
replication licensing factor proteins that were upregulated in NSCLC LDN (LOG2 
fold change>1 and p<0.05) versus CTL are shown in Figure 5.16. Eukaryotic 
minichromosome maintenance protein complex consists of six gene products 
(MCM2-7), which form a heterohexamer that is central to DNA replication initiation 
and elongation. MCM2-7 were all upregulated in NSCLC LDN versus CTL.  
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Figure 5.15: GeneMania103 network analysis of NSCLC low-density blood neutrophil 
upregulated proteins. 
Upregulated NSCLC low-density blood neutrophil (LDN) proteins (LOG2 fold change>1 and 
p<0.05) versus healthy donor control blood neutrophils. Translational initiation proteins 
highlighted in orange and DNA replication proteins in green. 
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Figure 5.16: NSCLC low-density blood neutrophils have increased DNA replication 
proteins. 
DNA replication licensing factor proteins upregulated in NSCLC low-density blood 
neutrophils (LOG2 fold change>1 and p<0.05) versus healthy donor control blood 
neutrophils, n=5. Analysed by t-test. Data represents mean ± SEM. CTL, healthy donor 
control neutrophils; LDN, low-density neutrophils.  
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5.2.12 NSCLC low-density blood neutrophils and pleural 
fluid neutrophils have pro-survival proteomic 
signatures 
Finally, to establish whether NSCLC LDN and NSCLC PFN had pro-survival 
proteomic signatures in keeping with NanoString™ transcription data, volcano plots 
highlighting differentially expressed apoptosis pathway proteins (KEGG) when 
compared with CTL were plotted (Figure 5.17A and B). These indicated that several 
pro-survival apoptosis proteins were upregulated (blue) and several pro-apoptosis 
proteins were downregulated (red), in both NSCLC LDN and NSCLC PFN, in 
keeping with the established phenotypes.  
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5.3  Discussion 
The data in this chapter provide novel insights into the transcriptome and proteome 
of advanced NSCLC neutrophil populations, identifying features that distinguish 
each of them, and that may also contribute to disease outcome. 
 
5.3.1 NSCLC low-density blood neutrophils are the most 
different 
Both transcriptomic and proteomic studies in this chapter confirm that NSCLC low-
density blood neutrophils are the most different from healthy donor blood 
neutrophils. This is followed by pleural fluid neutrophils (of which a subpopulation is 
likely to be migrated low-density neutrophils). NSCLC normal-density blood 
neutrophils are similar to healthy donor blood neutrophils. It was interesting to note 
that the protein distribution by abundance and mass was similar between all 
populations. NSCLC low-density blood neutrophils also had a similar amount of total 
protein to healthy donor blood neutrophils. Therefore, low-density neutrophils are 
not low-density due to total protein content.  
 
5.3.2 CD66b, LOX-1 and CD62L as advanced NSCLC 
neutrophil population markers 
Transcription of the genes coding for CD66b, LOX-1 and CD62L in NSCLC low-
density blood neutrophils and pleural fluid neutrophils, matched the pattern that 
would be expected from the flow cytometry data in the neutrophil populations 
chapter of this thesis. As well as confirming the population phenotypes, this 
strengthens the argument that the low-density blood population likely migrates into 
the pleural space. It builds upon the work of Condamine et al.,65 who identified LOX-
1 to be transcriptionally upregulated in, and also expressed at higher levels on the 
surface of, G-MDSCs in several human cancers including NSCLC. It must however 
be noted, that in this chapter the low-density blood neutrophil transcriptional 
signature seen, is a composite of both CD66+CD10+LOX-1- and CD66highCD10-LOX-
1+ subpopulations together (low-density blood neutrophils were analysed as a whole 
population).  
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5.3.3 Altered neutrophil granule proteins in advanced NSCLC 
The transcriptomic and proteomic data found in this chapter raises some interesting 
questions regarding neutrophil granule proteins. For a reminder of the different types 
of neutrophil granule and their proteins, refer back to Table 5.1. NSCLC low-density 
blood neutrophils were seen to have upregulated transcription of neutrophil granule 
proteins. This is in keeping with previous studies of low-density blood neutrophils in 
rheumatoid arthritis,160 psoriasis,162 and systemic lupus erythematosus.158 159 In fact, 
Teague et al. went on to perform transmission electron microscopy of psoriasis low-
density blood neutrophils, demonstrating they had more primary granules.162 Yet in 
apparent opposition to this transcriptomic data, the proteomic analysis of NSCLC 
neutrophils in this chapter indicated an overall downregulation of granule proteins in 
low-density blood neutrophils, and the suggestion of a similar pattern in pleural fluid 
neutrophils. It must be noted that the most downregulated low-density blood 
neutrophil granule proteins were pentraxin-3 and cathelicidin, both found in 
secondary granules, and azurocidin and arginase-1 found in primary granule 
proteins, were not downregulated at all. However, this mismatch between transcripts 
and proteins raises a couple of possibilities; that the neutrophils are degranulating, 
or that they have not finished producing granules yet i.e. an indication of immature 
cell status. Some possible evidence against degranulation comes from the human 
cytokine array analysis of pleural fluid supernatant: pentraxin-3 (found in secondary 
granules) and MMP-9 (found in tertiary granules) are not increased in the pleural 
fluid supernatant of NSCLC, when compared with pneumonia pleural fluid 
supernatant. In future work, transmission electron microscopy to look at granules in 
NSCLC low-density blood neutrophils, may provide added information for this 
debate.  
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5.3.4 Intrinsic features of NSCLC neutrophils contributing to 
the pro-survival phenotype 
The transcriptomic and proteomic signatures of NSCLC low-density blood 
neutrophils and pleural fluid neutrophils favour neutrophil survival, with 
downregulation of pro-apoptotic genes/ proteins, and upregulation of pro-survival 
genes/ proteins. Common features to both populations are downregulation in the 
transcription of the genes NF-kBI and FAS, and downregulation of the proteins BH3 
interacting domain death agonist and caspase 3/ caspase 8. This is particularly 
interesting, as there are strong correlations with the work of Wright et al. 
investigating low-density blood neutrophils in patients with rheumatoid arthritis.160 
They found that rheumatoid arthritis low-density blood neutrophils were also pro-
survival, with 20% apoptosis following 18 hours in culture. Furthermore, RNA-
sequencing revealed downregulation in the transcription of several highly relevant 
genes: BID, CASP8, NF-kBI, RELA, TNFRSF1A (CD120a) and TNFRSF1B 
(CD120b). In addition, they confirmed downregulation of CASP8, NF-kBI, RELA, 
TNFRSF1A and TNFRSF1B by quantitative polymerase chain reaction. Finally, they 
showed that if healthy donor blood neutrophils were exposed to recombinant TNFa, 
this reduced 18-hour apoptosis, but if rheumatoid arthritis low-density blood 
neutrophils were exposed to recombinant TNFa, there was no added survival 
benefit. This has strong parallels to the autologous pleural fluid supernatant 
experiments found in the cancer-specific neutrophil populations chapter of this 
thesis, where autologous supernatant (containing significant TNFa) did not trigger 
any added survival benefit in NSCLC blood neutrophils, but did reduce healthy 
donor blood neutrophil 20-hour apoptosis. It is therefore clear that altered TNF-
signalling is important to neutrophil survival, resulting in sustained inflammation in 
both rheumatoid arthritis and NSCLC. This has never been shown before in NSCLC. 
Future supportive work would include quantitative polymerase chain reaction of NF-
kBI, FAS and CASP8 in NSCLC low-density blood neutrophils.  
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5.3.5 Increased translational initiation in NSCLC low-density 
blood neutrophils 
Proteomic studies revealed NSCLC low-density blood neutrophils to have 
upregulation of translational initiation, with increased ribosomal proteins and 
eukaryotic translation initiation factors. This has previously been seen in human 
cancer low-density blood neutrophils (samples including NSCLC), where elevation 
of eukaryotic translation initiation factors 2 and 4 was observed.65 Of interest, in 
systemic lupus erythematosus it was the CD10- subset of low-density blood 
neutrophils with immature banded nuclei, that were seen to be more transcriptionally 
active, with more peaks in the promoter regions found by assay for transposase-
accessible chromatin (ATAC) sequencing.158 It would be interesting to define said 
features of NSCLC low-density blood CD66+CD10+LOX-1- and CD66highCD10-LOX-
1+ neutrophil subpopulations in future work. 
 
5.3.6 Upregulation of DNA replication proteins in NSCLC low-
density blood neutrophils 
It is reported in this chapter the NSCLC low-density blood neutrophils have 
upregulation of DNA replication proteins. This has not been previously published in 
human cancer research. It has been observed in rheumatoid arthritis, with increased 
cell-cycle gene transcripts and upregulation of CDK2, CDK4 and CDK6 by 
quantitative polymerase chain reaction in low-density blood neutrophils. 
Furthermore, 1% stained for the G2/S phase of the cell cycle.160 In addition this was 
observed in systemic lupus erythematosus bioinformatics study,159 but was a 
questionable finding due to contamination of the original datasets with other cells. 
However, it was confirmed in another systemic lupus erythematosus study, where 
upregulation of genes for cell cycle progression were found in the immature subset 
of low-density blood neutrophils.158 Future work should include analysis of NSCLC 
low-density blood neutrophil cell cycle and proliferation by flow cytometry, for 
example by combining Ki67 and Hoechst 33342.174  
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5.3.7 Other low-density blood neutrophil transcriptomic and 
proteomic signatures of interest: type I interferons and 
S100A8/A9 
In systemic lupus erythematosus, low-density blood neutrophils are thought to 
contribute to vascular disease through mechanisms including release of type I 
interferons that disrupt the function of vascular endothelial cells. Mistry et al. carried 
out transcriptomics of mature and immature low-density blood neutrophil subsets in 
systemic lupus erythematosus, noting that the mature subset of low-density blood 
neutrophils had upregulation of type I interferon signalling.158 Increased type I 
interferon transcriptional signatures in low-density neutrophils have also been found 
to be associated with worse outcome in other diseases e.g. malaria.175 In the 
transcriptomic and proteomic analysis of NSCLC low-density blood neutrophils 
carried out here, there were no significant changes in type I interferon signalling 
pathways. It must be noted, in contrast to the diseases described above, in cancer 
research, type I interferons have been associated with anti-tumour responses and 
lack of type I interferons associated with increased metastasis.26 145 
Proteomics studies in systemic lupus erythematosus have identified S100A9 as a 
signature for low-density blood neutrophils.176 Interestingly, in the transcriptomic 
analysis of NSCLC low-density blood neutrophils carried out in this chapter, S100A8 
and S100A9 were both found to be upregulated. S100A8 and S100A9 were also 
ranked in the top 25 proteins by abundance in the proteomic studies of this chapter. 
In mouse models of malignancy, S100A8/A9 proteins have been shown to regulate 
the accumulation of MDSCs.66 Indeed in models of colon cancer, MDSCs have been 
found to produce S100A8/A9, leading to an autocrine pathway for accumulation of 
MDSCs at metastatic sites, and furthermore, S100A8/A9 activated tumour cells 
promoting cancer progression.67 Additionally, S100A8/A9 is also important in lung 
metastasis models, promoting the pre-metastatic niche through recruitment of 
myeloid cells.54 177  
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5.3.8 Wider interpretation of the data 
The data in this chapter shows that NSCLC normal-density blood neutrophils are 
quite similar to healthy donor blood neutrophils in their transcriptomic and proteomic 
signatures. NSCLC low-density blood neutrophils have the most differences. 
NSCLC Pleural fluid neutrophils have some key differences, but likely reflect a 
combination of both blood populations that have migrated to the pleural space 
(which could explain why some of the low-density blood neutrophil signatures are 
lost in the pleural fluid neutrophil signatures). In addition, expression of neutrophil 
surface marker genes in this chapter match the phenotyping found in previous 
chapters of this thesis. 
The key findings of this chapter (Figure 5.18) are that NSCLC low-density blood 
neutrophils have increased transcription of granule proteins, but reduced total 
granule protein, compared with healthy donor blood neutrophils. Of note, it is the 
primary granule proteins that are actually present in NSCLC low-density blood 
neutrophils. NSCLC low-density neutrophils have increased translational initiation 
and upregulation of DNA replication proteins versus healthy donor blood neutrophils. 
NSCLC low-density blood neutrophils do not upregulate type I interferons, but do 
upregulate S100A8/A9. Both NSCLC low-density blood neutrophils and pleural fluid 
neutrophils have pro-survival transcriptomic and proteomic signatures. 
A key question this raises, is whether NSCLC low-density blood neutrophils are 
proliferating, and what impact this has upon the ability of these cells to carry out 
other functions e.g. pro- or anti-tumour activity. 
It is widely known that acute inflammation/ infection, leads to a ‘left shift’ of the bone 
marrow with emergency granulopoeisis and release of immature neutrophils into the 
circulation. In this setting, the immature neutrophils are functional. However, in 
chronic inflammatory states, it would appear that this pressure on the bone marrow 
to release immature cells remains, but that the recruited immature cells are 
dysfunctional. The degree to which low-density blood neutrophils represent 
immature cells prematurely released from the marrow is debated.178 Nonetheless, 
the data in this chapter supports the notion that, at least, the immature NSCLC low-
density blood neutrophil subpopulation is indeed this. The mature NSCLC low-
density blood neutrophil subpopulation may be something different, for example they 
may represent cells that have been modulated by their local tissue environment. 
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Yet, it must be noted that for the data in this chapter, all NSCLC low-density blood 
neutrophils were considered as a single population together. Reasoning for these 
theories will now be explained. 
Transcriptomic and proteomic studies of neutrophils at various stages of 
development, have shown that neutrophil granules are produced at an immature 
stage of development in a controlled order.171 172 Primary granules are formed during 
the myeloblast to promyelocyte stage, secondary during myelocyte to 
metamyelocyte stage and tertiary from the band cell to segmented cell.17 The 
dogma is that mature neutrophils do not form new granules. The data from this 
chapter would fit with NSCLC low-density granulocytes being akin to myelocytes/ 
metamyelocytes i.e. formed primary granules and starting to produce their next 
granules. The nuclear morphology shown in previous chapters could also be in 
keeping with this. Of note, it has also been postulated in the literature that neutrophil 
nuclear morphology determines which parts of DNA are available to transcribe, 
resulting if a different balances of gene transcription, with the consequence of 
altered functional outcomes.178 In conjunction with this, myelocytes/ metamyelocytes 
are known to have downregulation of pro-apoptotic transcripts for genes TNFRSF1A 
(CD120a), FADD, CASP8 and BID.171 This pro-survival phenotype has uncanny 
similarities to that seen in this chapter in NSCLC low-density blood neutrophils and 
pleural fluid neutrophils. The upregulation of S100A8/A9 proteins in NSCLC low-
density blood neutrophils and NSCLC neutrophil population apoptosis phenotypes, 
would support a model of persistent neutrophilic inflammation and recruitment. 
It is interesting that NSCLC low-density blood neutrophils do not upregulate type I 
interferon signalling in contrast to those found in systemic lupus erythematosus. This 
highlights the fact that these diseases are quite different, and that parallels between 
studies of cancer neutrophil populations and autoimmune/ inflammatory disease 
neutrophil populations can only be taken so far. Indeed, in the literature low-density 
neutrophils in autoimmune diseases are considered to be of a predominant ‘pro-
inflammatory’ phenotype, whereas those in cancer are seen to have a 
predominantly ‘immunosuppressive’ phenotype.179 
The limitations of the data in the chapter are that it provides avenues that will be 
important to explore going forward, but more functional studies of each NSCLC 
neutrophil population are needed. For example, cell cycle studies of low-density 
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neutrophils are needed. T cell proliferation studies would confirm which populations/ 
subpopulations are immunosuppressive (although this has been done previously to 
an extent by Condamine et al.65 see 5.1.2). It would also be very informative to study 
the NSCLC immature and mature low-density blood neutrophil populations 
separately, to tease apart which are responsible for the features observed in this 
chapter. Other limitations include the fact that there is no direct evidence of the 
effect these populations have upon tumour cells themselves. In addition, the 
proteomic data was limited by the relatively small number of neutrophils used, 
leading to loss of detection of low-abundance proteins. Changes in these low-
abundance proteins could be of functional importance. Finally, whether there is any 
degree of plasticity in the function of neutrophils that have migrated to pleural space, 
needs to be investigated.  
 
5.3.9 Summary 
This chapter provides evidence that implies NSCLC low-density blood neutrophils 
represent immature cells that have been recruited from the bone marrow. In 
addition, it suggests that they retain proliferative capacity, have reduced neutrophil 
granules, and are pro-survival. These features are likely to impact upon their 
function at the pleural metastatic site; they favour sustained and ineffective 
inflammation, but further functional studies are needed to clarify this.  
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Figure 5.18: The transcriptome and proteome of NSCLC low-density blood neutrophils 
compared with healthy donor blood neutrophils. 
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Chapter 6 General discussion and future 
directions 
 
6.1 Summary of key findings 
Neutrophils are considered to be active players in the metastatic environment, 
forming an important part of the tumour niche. Neutrophil populations have been 
described in early stage human lung cancer, and animal models have demonstrated 
their importance in both pre-metastatic and established metastatic sites. However, 
to date there is limited data regarding human neutrophil populations in advanced 
lung cancer and their role. Furthermore, the underlying drivers of neutrophil 
behaviour at metastatic sites needs to be delineated, and could identify new 
therapeutic targets for immunomodulation in advanced malignancy. 
The aims of this project were to investigate how neutrophil function is influenced by 
extrinsic signals in the NSCLC pleural metastatic microenvironment, define the 
neutrophil populations present in advanced NSCLC, and explore whether intrinsic 
properties of neutrophil populations in advanced NSCLC may define their role. 
In this study, neutrophils were extracted from the pleural fluid (from the pleural 
metastatic site) and blood of patients with advanced NSCLC, so that their features 
and function could be determined. Blood and pleural fluid neutrophils were 
compared with those from patients with pneumonia (where neutrophil responses are 
generally appropriate and effective) and with blood neutrophils from healthy donors. 
This enabled the identification of cancer-specific signatures. 
 
6.1.1 The NSCLC pleural environment influences neutrophil 
function 
It is well known that malignant pleural metastatic site is hypoxic.113-116 This study 
confirmed that it is also cytokine-rich, and has variable levels of glucose. Human 
cytokine array and ELISA studies, demonstrated that the cytokine profile of NSCLC 
pleural fluid is different to that seen in acute infection, favouring a phenotype of 
sustained and immunosuppressive inflammation.  
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The NSCLC pleural environment was modelled in vitro by culturing healthy donor 
neutrophils in conditions emulating the pleural space and observing the impact of 
these manipulations (i.e. oxygen/ glucose availability and cell conditioning with 
pleural fluid supernatant). This provided evidence that the NSCLC pleural 
environment conditions neutrophils into a state of persistent counterproductive 
inflammation. TNFa and hypoxia acted as pro-survival signals leading to neutrophil 
persistence. NSCLC pleural fluid conditioned neutrophils to suppress CD8+ T cells 
through mechanisms that included PD-L1 expression.  
The data described above is novel, as human tissue from the NSCLC pleural 
metastatic site has not been used in this way before. However, there were several 
limitations. Firstly, freshly extracted blood neutrophils were used for in vitro culture, 
rather than recruited neutrophils from a target site. It may be that changes 
neutrophils undergo during the process of recruitment from the blood, are relevant to 
their response at the target pleural site. Secondly, when PD-L1 inhibitors were used, 
they only partially reversed the suppression of CD8+ T cells by NSCLC pleural fluid-
conditioned neutrophils. There were therefore other mechanisms of suppression that 
have not been identified. The mechanism by which NSCLC pleural fluid conditions 
neutrophils to express PD-L1 has not been found either. Finally, suppression of the 
adaptive immune response is an indirect measure of neutrophil pro- or anti-tumour 
activity, and direct assays e.g. using cancer cell lines, were not utilised. 
 
6.1.2 There are cancer-specific neutrophil populations in 
advanced NSCLC 
To establish the phenotype of neutrophil populations in advanced NSCLC, cellular 
morphology, surface marker expression and functional assays were utilised. In order 
to find correlations across the different cell compartments, neutrophils from the 
blood where compared with neutrophils from the pleural space.  
There was an expanded population of low-density blood neutrophils in advanced 
NSCLC, that were not present in health, and a proportion of which were immature 
with banded nuclei. A subpopulation of advanced NSCLC low-density neutrophils 
was CD66high, immature (CD10-), activated (CD62L-) and positive for a G-MDSC 
marker (LOX-1+). There was further evidence that these cells were also present in 
NSCLC pleural fluid, but in contrast these cells were not present in pneumonia 
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pleural fluid. NSCLC pleural fluid neutrophils expressed PD-L1 and were long-lived 
with increased CD120b expression (pro-survival TNFa receptor). Together this was 
suggestive that advanced NSCLC pleural fluid neutrophils may contribute to an 
environment of sustained inflammation that is immunosuppressive. 
This data was particularly interesting, as the advanced NSCLC neutrophil population 
phenotypes identified were the exact opposite of those attributed to neutrophils in 
early stage NSCLC, where neutrophils are believed to be helpful at the primary 
tumour site.46 47 57 
A key limitation of the above data, is that T cell co-culture assays were not carried 
out using patient-derived neutrophils. The data also raised further questions that 
have not been answered. Autologous pleural fluid supernatant did not act as a 
survival signal to NSCLC neutrophils at 20 hours. It may be that this was because 
cell-intrinsic changes in apoptosis pathways, or other environmental signals e.g. 
hypoxia, were more powerful drivers of survival. 
 
6.1.3 Intrinsic properties of neutrophil populations in 
advanced NSCLC define their function 
In order to explore whether intrinsic properties of neutrophil populations in advanced 
NSCLC dictate their role, NSCLC low-density blood neutrophils, NSCLC normal-
density neutrophils and NSCLC pleural fluid neutrophils, were defined by their 
transcriptomic and proteomic signatures.  
This provided evidence that implied NSCLC low-density blood neutrophils represent 
immature cells that have been recruited from the bone marrow. NSCLC low-density 
blood neutrophils appear to retain proliferative capacity (upregulation of DNA 
replication proteins), are translationally active (upregulation of translational initiation 
proteins), have reduced neutrophil granule proteins (in the context of upregulated 
neutrophil granule gene transcripts), and are pro-survival (both in apoptosis proteins 
expressed and gene transcripts). These features are likely to impact upon their 
function once recruited to the pleural metastatic site; favouring sustained and 
ineffective inflammation. 
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Whilst there is transcriptomic data for human cancer neutrophil populations, to date, 
there have not been any publications regarding the proteome of human cancer 
neutrophil populations. A strength of this study is that the transcriptomic data could 
be directly compared with the proteomic data to look for connections and also to 
highlight discordance. A further strength of the proteomic data is that this unbiased 
approach leads to the identification of novel changes. A weakness of the data, was 
that by using a targeted transcriptomic assay, some gene transcripts of interest were 
not measured. Another weakness is that being limited to small numbers of 
neutrophils for proteomics, meant that detection of some low abundance proteins, 
which may be important, will have been lost. Finally, it must be remembered that 
whilst this –omics data raises some very interesting findings and theories, these 
need to be confirmed or refuted through functional studies. 
A final consideration is what this thesis says in terms of how the neutrophil 
populations described correlate to neutrophil populations described elsewhere in 
cancer research, and whether some of the terminology used in the literature can be 
harmonised. The data presented here, would point toward G-MDSC and immature 
low-density neutrophils being one and the same population, reflecting a 
dysregulation of bone marrow neutrophil release, resulting in an expanded 
dysfunctional immature circulating neutrophil population, with detrimental actions 
when recruited to the target site. The data also highlights the importance of both the 
local tissue environment and intrinsic programming, in determining neutrophil 
function. 
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6.2 Future directions 
 
6.2.1 Pleural environment 
It is interesting that NSCLC pleural fluid glucose is not low. This could be because it 
is being replenished, but another explanation may be that immune cells are not 
utilising it. It would therefore be of intrigue to explore what form of metabolism 
NSCLC neutrophil populations carry out.  
In terms of NSCLC pleural fluid supernatant conditioning of healthy donor 
neutrophils, transcriptomics, proteomics or cytokine profiling of the conditioned cells, 
could give more information regarding how pleural fluid supernatant does this. 
Indeed, it would be informative to investigate whether NSCLC pleural fluid 
supernatant can condition bone marrow neutrophils of healthy donors i.e. immature 
cells, or pleural fluid neutrophils from pneumonia patients into a ‘pro-tumour’ state. 
With regard to T cell co-culture studies, these could be repeated with pneumonia 
pleural fluid supernatant to see if the phenotype is different. Furthermore, to 
thoroughly interrogate the mechanism of T cell suppression by NSCLC pleural fluid-
conditioned neutrophils, mechanisms other than PD-L1 e.g. arginase or reactive 
oxygen species, should be sought. In addition, separate experiments using cancer 
cell lines could be used to look directly at pro- or anti-tumour activity of pleural fluid-
conditioned neutrophils. 
 
6.2.2 NSCLC neutrophil populations 
Whilst it seems likely that the CD66bhighCD11b+CD15+CD14-CD49d-CD10-CD62L-
LOX-1+ NSCLC low-density neutrophil population identified represents the 
neutrophils with banded nuclei seen by cellular morphology, this needs to be 
proven. One approach would be to use fluorescence-activated cell sorting to isolate 
the cells and then make cytospins to observe their morphology. 
The data would also suggest that autologous pleural fluid supernatant (and therefore 
possibly TNFa) does not act as a survival signal for NSCLC neutrophils (at 20 
hours). Future work could use longer time points or recombinant TNFa to test this 
further. 
Chapter 6 Discussion  
198   
To test whether NSCLC neutrophil populations are pro- or anti- tumour with a 
functional assay, T cell co-culture (or tumour cell line co-culture) needs to be carried 
out with NSCLC neutrophil populations (although this has been done previously to 
an extent with NSCLC blood neutrophil populations by Condamine et al.65). 
Lastly, it would helpful to test whether NSCLC neutrophil populations display 
plasticity, for example by investigating whether they can by polarised to an anti-
tumour phenotype through exposure to IFNb. 
 
6.2.3 Avenues highlighted by –omics studies 
In order to prove that NSCLC low-density blood neutrophils are proliferative, 
analysis of cell cycle and proliferation is needed e.g. by flow cytometry combining 
Ki67 and Hoechst 33342. In addition, it would be highly informative to carry out 
transcriptomic and proteomic studies with pneumonia neutrophil populations to see 
how they differ from cancer. Finally, in future work it may be pertinent to study the 
immature and mature low-density neutrophil populations separately, as they may 
have important differences.  
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6.3 Conclusions 
To summarise, this study defines the neutrophil populations present in advanced 
NSCLC and the influence of the NSCLC pleural metastatic environment upon their 
function, as well as their intrinsic features. The data favours a phenotype of 
sustained neutrophilic inflammation that is immunosuppressive at the metastatic 
site, with a subpopulation of immature cells. A more complete understanding of the 
mechanisms, and proof of neutrophil functional impact upon tumour outcome, may 
help to identify new therapeutic targets for immunomodulation in advanced cancer. 
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NSCLC Low Density Neutrophils versus Healthy Donor Controls 
 
Probe	Name Log2	Fold	Change p value
NKG7 6 95 0 0003
CEACAM8 6 18 0 0000
MMP8 6 13 0 0012
CTSG 5 62 0 0012
RNASE2 5 47 0 0001
RNASE3 5 43 0 0065
CAMP 5 34 0 0000
MPO 5 16 0 0002
CYBB 4 66 0 0004
ANXA1 4 61 0 0004
ARG1 4 19 0 0003
PGLYRP1 3 91 0 0007
LGALS3 3 74 0 0001
TMEM173 3 72 0 0187
COL17A1 3 53 0 0001
H ST1H1C 3 46 0 0001
ANXA4 3 45 0 0020
PTGER2 3 40 0 0002
TOP2A 3 30 0 0028
OLR1 3 30 0 0186
CLEC5A 2 88 0 0008
FCN1 2 78 0 0031
LTA4H 2 76 0 0001
CASP10 2 71 0 0000
CLC 2 47 0 0457
S100A8 2 46 0 0057
CEACAM1 2 45 0 0158
FUT4 2 43 0 0004
CEBPA 2 41 0 0100
TM7SF3 2 39 0 0007
TUBB 2 30 0 0021
PTX3 2 20 0 0268
ERG 2 18 0 0045
SPTBN1 2 17 0 0006
MMP9 2 08 0 0313
L18 2 01 0 0162
FAF1 1 99 0 0005
CALR 1 93 0 0026
SERP NB6 1 82 0 0049
GSN 1 80 0 0041
CD47 1 77 0 0025
HPRT1 1 75 0 0004
NOL7 1 74 0 0016
TGB1 1 66 0 0009
TGAM 1 63 0 0217
L18R1 1 60 0 0299
TNFA P8 1 59 0 0040
PFDN6 1 56 0 0033
S100A9 1 56 0 0244
GUSB 1 51 0 0082
GRN 1 50 0 0169
TXN 1 41 0 0235
PRDX3 1 37 0 0091
C3AR1 1 36 0 0305
ETS1 1 36 0 0130
HMGB1 1 32 0 0185
MAPK14 1 23 0 0435
H ST2H2AA3 1 21 0 0009
TRAF2 1 03 0 0102
B RC5 1 03 0 0326
KZF1 1 02 0 0072
   
  213 
              
Probe	Name Log2	Fold	Change p value
DNAJC14 1 02 0 0100
MAP2K4 1 03 0 0028
CTSS 1 04 0 0324
H VEP1 1 06 0 0295
MAPK13 1 06 0 0268
PSME2 1 06 0 0035
TLR6 1 08 0 0082
C4A 1 08 0 0395
NR2F6 1 09 0 0058
MMP1 1 11 0 0202
CYT P 1 12 0 0351
B D 1 15 0 0190
CXCL13 1 16 0 0121
TUBA1A 1 16 0 0401
L1RL1 1 17 0 0462
FPR3 1 18 0 0160
SK L 1 18 0 0008
CXCL3 1 18 0 0156
ER3 1 20 0 0278
CCL23 1 22 0 0184
NS G1 1 22 0 0027
COSLG 1 24 0 0314
SMAD1 1 25 0 0012
PLAU 1 26 0 0288
TGAX 1 26 0 0445
PRRX1 1 26 0 0172
NAMPT 1 27 0 0284
STAT6 1 27 0 0315
MAFB 1 27 0 0223
CXCR4 1 28 0 0047
FAS 1 28 0 0040
L27RA 1 29 0 0009
YES1 1 29 0 0020
GF1 1 30 0 0144
VAMP2 1 31 0 0047
CD36 1 32 0 0128
ADORA3 1 32 0 0291
ADAMTS17 1 32 0 0233
HOXD4 1 35 0 0374
CD1C 1 36 0 0018
DDR2 1 36 0 0061
TLR10 1 36 0 0020
PSMB9 1 37 0 0193
BMP8A 1 38 0 0108
RGS6 1 39 0 0317
P M2 1 40 0 0221
TLR3 1 40 0 0352
TNFSF9 1 41 0 0354
L9 1 42 0 0348
SERP NB7 1 42 0 0014
SQSTM1 1 43 0 0004
TAPBP 1 48 0 0185
MX2 1 49 0 0034
MAPK11 1 49 0 0164
SELE 1 50 0 0255
K TLG 1 50 0 0004
KCNAB1 1 50 0 0286
L5RA 1 51 0 0377
STAT1 1 53 0 0017
COL1A2 1 53 0 0270
TAP1 1 55 0 0194
GATA2 1 55 0 0212
CXCL5 1 55 0 0315
Probe	Name Log2	Fold	Change p value
CCL20 1 58 0 0383
CCL11 1 58 0 0389
CLEC1B 1 58 0 0276
CDKN1A 1 59 0 0243
ANOS1 1 60 0 0442
TNFSF4 1 61 0 0413
CD34 1 62 0 0461
CD70 1 64 0 0201
CXCL9 1 64 0 0379
TNFA P6 1 64 0 0243
TLR9 1 65 0 0067
XCR1 1 65 0 0376
CETP 1 68 0 0098
DO1 1 68 0 0486
TREX1 1 68 0 0002
GPR65 1 69 0 0126
CCL22 1 69 0 0386
GEM 1 70 0 0062
RF1 1 70 0 0082
C1QB 1 71 0 0011
TNFRSF12A 1 72 0 0419
NFKB E 1 72 0 0061
CD40LG 1 73 0 0036
ENPEP 1 74 0 0266
LAMB2 1 74 0 0313
CXCL16 1 74 0 0135
CXCL11 1 75 0 0022
CD80 1 75 0 0370
L3 1 75 0 0071
ROS1 1 76 0 0292
SERP NB9 1 76 0 0230
ABCC8 1 76 0 0471
FNG 1 77 0 0489
LPL 1 77 0 0228
RGS16 1 78 0 0217
B RC3 1 79 0 0122
CCL14 1 80 0 0119
MSC 1 80 0 0008
ACOT1 1 80 0 0225
CCL26 1 81 0 0100
MMP19 1 81 0 0296
CX3CR1 1 81 0 0023
NOD2 1 81 0 0196
FSCN1 1 82 0 0139
CTLA4 1 83 0 0367
ANGPT1 1 84 0 0047
CXCL2 1 84 0 0016
DPP4 1 84 0 0383
NR1H3 1 85 0 0211
CAM1 1 85 0 0170
CCR5 1 86 0 0158
ADAMTS9 1 86 0 0131
L27 1 86 0 0075
MPEG1 1 87 0 0089
RGL1 1 89 0 0008
ACOD1 1 89 0 0315
PROS1 1 90 0 0115
CD276 1 91 0 0082
CRABP2 1 91 0 0176
CLEC7A 1 92 0 0140
OSM 1 92 0 0058
L12A 1 92 0 0298
RAPGEF4 1 92 0 0237
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Probe	Name Log2	Fold	Change p value
FZD4 1 94 0 0421
CXCR5 1 96 0 0177
SPHK1 1 96 0 0135
L33 1 97 0 0488
VTCN1 1 97 0 0232
RND3 1 98 0 0124
CCR7 1 99 0 0433
L15 1 99 0 0256
COL12A1 2 00 0 0288
GATA3 2 00 0 0253
PLAUR 2 02 0 0008
NR4A1 2 02 0 0421
RASAL1 2 04 0 0496
CD1E 2 05 0 0051
COL11A1 2 08 0 0306
CSF1R 2 08 0 0354
CCL16 2 09 0 0191
L1RN 2 10 0 0300
HES4 2 11 0 0079
MAP3K14 2 11 0 0047
ADAMTS3 2 12 0 0159
CCL2 2 12 0 0333
ADAMTS14 2 13 0 0005
PF4 2 13 0 0039
L23A 2 14 0 0205
MRC1 2 14 0 0498
EN1 2 15 0 0041
HNF1B 2 15 0 0028
CCL25 2 15 0 0077
DO2 2 16 0 0146
TAP2 2 16 0 0026
SG15 2 17 0 0034
CDH2 2 17 0 0062
SOCS1 2 19 0 0107
TNFRSF8 2 20 0 0007
CXCL8 2 20 0 0240
MAFF 2 20 0 0046
CD247 2 22 0 0041
MARCKSL1 2 23 0 0029
L1A 2 24 0 0378
GADD45B 2 25 0 0002
TREM2 2 25 0 0027
TNFRSF1B 2 27 0 0049
TNFRSF14 2 27 0 0018
NFKB A 2 31 0 0044
KRBA1 2 33 0 0332
ZKSCAN5 2 35 0 0010
CREM 2 40 0 0175
BMP6 2 42 0 0002
CYP3A4 2 42 0 0033
COL3A1 2 45 0 0359
LAMB3 2 47 0 0034
TNF 2 52 0 0016
SERP NE3 2 57 0 0045
TNFA P3 2 58 0 0010
DUSP2 2 64 0 0030
FGF10 2 65 0 0033
CD14 2 68 0 0107
F T1 2 72 0 0215
CCL3 2 74 0 0357
HLA DOB 2 81 0 0002
CD83 2 95 0 0027
L1B 3 31 0 0137
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Appendix 2: List of statistically significant differentially 
expressed proteins 
NSCLC Normal Density Neutrophils versus Healthy Donor Controls 
 
Protein	names Log2	fold	change Log10	p value
60S	r bosoma 	prote n	L34 2 68 3 66
Vacuo ar	prote n sort ng assoc ated	prote n	25 2 05 1 94
F am n nteract ng	prote n	FAM101B 2 04 1 79
Armad o	repeat conta n ng	prote n	8 1 98 1 44
Neutroph 	defens n	4 1 97 1 77
nos to 	monophosphatase	2 1 95 1 64
SCY1 ke	prote n	2 1 84 1 72
COMM	doma n conta n ng	prote n	3 1 80 2 99
Park nson	d sease	7	doma n conta n ng	prote n	1 1 78 2 12
R bonuc eos de d phosphate	reductase	 arge	subun t 1 76 1 85
Programmed	ce 	death	prote n	4 1 74 1 85
COP9	s gna osome	comp ex	subun t	3 1 73 1 43
40S	r bosoma 	prote n	S28 1 64 2 19
M tochondr a 	d carboxy ate	carr er 1 61 1 36
B funct ona 	3 phosphoadenos ne	5 phosphosu fate	synthase	1 1 59 1 36
M crotubu e act n	cross nk ng	factor	1,	 soforms	1/2/3/5 1 58 1 99
N F3 ke	prote n	1 1 58 1 59
Pyr doxa dependent	decarboxy ase	doma n conta n ng	prote n	1 1 57 1 67
Lon	protease	homo og,	m tochondr a 1 56 1 54
DNA	rep cat on	 cens ng	factor	MCM7 1 55 1 73
sopenteny d phosphate	De ta somerase	1 1 54 2 09
COMM	doma n conta n ng	prote n	1 1 52 2 37
COP9	s gna osome	comp ex	subun t	1 1 51 1 65
ntraf age ar	transport	prote n	25	homo og 1 50 1 42
Gamma tubu n	comp ex	component	2 1 50 1 37
CWF19 ke	prote n	1 1 47 1 84
Caspase 10;Caspase 10	subun t	p23/17;Caspase 10	subun t	p12 1 47 2 26
DDB1 	and	CUL4 assoc ated	factor	7 1 47 1 79
Vacuo ar	prote n	sort ng assoc ated	prote n	13C 1 46 1 31
Nuc ear	pore	comp ex	prote n	Nup133 1 46 2 05
Leuc ne r ch	PPR	mot f conta n ng	prote n,	m tochondr a 1 44 1 36
Ub qu t n con ugat ng	enzyme	E2	K 1 43 1 65
Putat ve	N acety g ucosam ne 6 phosphate	deacety ase 1 40 1 54
Ser ne/threon ne prote n	k nase	17B 1 38 1 75
Ub qu t n con ugat ng	enzyme	E2	var ant	3 1 38 1 30
UDP g ucose	6 dehydrogenase 1 37 1 70
Ethy ma ony CoA	decarboxy ase 1 34 1 39
SH3	doma n b nd ng	g utam c	ac d r ch ke	prote n 1 31 1 53
C term na b nd ng	prote n	2 1 27 1 79
WD	repeat conta n ng	prote n	82 1 24 3 59
Tubu n spec f c	chaperone	D 1 24 2 43
Euka yot c	trans at on	e ongat on	factor	1	eps on 1 1 23 1 35
Catecho 	O methy transferase 1 22 1 34
60S	r bosoma 	prote n	L35a 1 21 1 44
NAD dependent	prote n	deacy ase	s tu n 5,	m tochondr a 1 21 3 96
Acy oxyacy 	hydro ase 1 18 1 35
GH3	doma n conta n ng	prote n 1 17 1 74
GTPase	NRas 1 15 2 54
Co d nduc b e	RNA b nd ng	prote n 1 14 1 49
Phosphomeva onate	k nase 1 14 1 97
Prote n	argonaute 4 1 13 1 31
Deoxycyt d ne	k nase 1 12 1 65
mpo t n 11 1 09 1 41
TNF	receptor assoc ated	factor	2 1 07 2 09
Capr n 1 1 06 1 53
Catheps n	D;Catheps n	D	 ght	cha n;Catheps n	D	heavy	cha n 1 00 1 59
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Protein	names Log2	fold	change -Log10	p-value
Serine/threonine protein	kinase	WNK1 1.01 2.22
High	mobility	group	protein	B1 1.08 2.15
FAS associated	death	domain	protein 1.16 1.43
Histone	H1x 1.16 2.47
Voltage gated	hydrogen	channel	1 1.18 1.34
Complement	C4 B 1.43 1.84
Histone	H1.0;Histone	H1.0,	N terminally	processed 1.46 2.23
High	affinity	copper	uptake	protein	1 1.67 1.45
Histone	H2B	type	1 O;Histone	H2B	type	1 B 1.78 1.42
Protein	quaking 1.78 1.75
WAS/WASL interacting	protein	family	member	1 2.40 1.34
  
218   
NSCLC Low Density Neutrophils versus Healthy Donor Controls 
 
Protein	names Log2	fold	change -Log10	p-value
DNA	rep cat on	 cens ng	factor	MCM4 4.47 2.21
DNA	rep cat on	 cens ng	factor	MCM3 3.94 1.93
DNA	rep cat on	 cens ng	factor	MCM5 3.84 2.21
DNA	rep cat on	 cens ng	factor	MCM6 3.80 2.02
DNA	rep cat on	 cens ng	factor	MCM7 3.53 1.90
DNA	rep cat on	 cens ng	factor	MCM2 3.22 1.53
Leuc ne-r ch	PPR	mot f-conta n ng	prote n,	m tochondr a 2.86 2.33
DNA	m smatch	repa r	prote n	Msh6 2.66 2.37
60S	r bosoma 	prote n	L35a 2.63 1.64
R bonuc eos de-d phosphate	reductase	 arge	subun t 2.57 2.26
40S	r bosoma 	prote n	S21 2.31 2.84
Neutroph 	defens n	4 2.21 1.74
Structura 	ma ntenance	of	chromosomes	prote n	2 2.13 1.42
Insu n-degrad ng	enzyme 2.08 1.59
Pter n-4-a pha-carb no am ne	dehydratase 2.07 1.41
60S	r bosoma 	prote n	L34 2.07 1.40
UDP-g ucose	6-dehydrogenase 2.04 1.97
40S	r bosoma 	prote n	S28 2.01 1.68
Ub qu t n-conjugat ng	enzyme	E2	K 2.01 1.45
Deoxynuc eos de	tr phosphate	tr phosphohydro ase	SAMHD1 2.01 1.42
A pha-L- duron dase 1.98 2.17
Pyr doxa -dependent	decarboxy ase	doma n-conta n ng	prote n	1 1.94 1.46
NADH	dehydrogenase	[ub qu none]	1	a pha	subcomp ex	subun t	13 1.91 1.56
60S	ac d c	r bosoma 	prote n	P2 1.89 1.36
Kerat nocyte-assoc ated	prote n	2 1.86 2.40
60S	r bosoma 	prote n	L27a 1.85 1.41
GTP:AMP	phosphotransferase	AK3,	m tochondr a 1.82 1.88
Ac d c	f brob ast	growth	factor	 ntrace u ar-b nd ng	prote n 1.80 2.05
Methy osome	prote n	50 1.79 1.86
Pro ferat ng	ce 	nuc ear	ant gen 1.77 2.11
40S	r bosoma 	prote n	SA 1.76 1.32
RNA-b nd ng	prote n	4 1.75 1.49
Armad o	repeat-conta n ng	prote n	8 1.70 1.91
Traff ck ng	prote n	part c e	comp ex	subun t	3 1.70 1.42
H stone- ys ne	N-methy transferase	setd3 1.69 3.27
COMM	doma n-conta n ng	prote n	3 1.65 2.04
A pha-N-acety ga actosam n dase 1.57 1.57
Tr part te	mot f-conta n ng	prote n	16 1.53 1.50
Exosome	comp ex	component	RRP42 1.53 1.47
Pept de-N(4)-(N-acety -beta-g ucosam ny )asparag ne	am dase 1.52 2.26
Sept n-11 1.50 2.37
Prote n	farnesy transferase/gerany gerany transferase	type-1	subun t	a pha 1.49 1.59
60S	r bosoma 	prote n	L8 1.47 2.69
Po y	[ADP-r bose]	po ymerase	1 1.47 1.58
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Protein	names Log2	fold	change -Log10	p-value
60S	r bosoma 	prote n	L22 1.46 2.69
Vacuo ar	prote n	sort ng-assoc ated	prote n	28	homo og 1.45 1.39
Catheps n	D;Catheps n	D	 ght	cha n;Catheps n	D	heavy	cha n 1.42 1.91
Transcr pt on	 ntermed ary	factor	1-beta 1.40 1.44
COP9	s gna osome	comp ex	subun t	1 1.37 1.61
Prote n	arg n ne	N-methy transferase	1 1.37 1.96
ATP-dependent	RNA	he case	DHX36 1.36 2.48
Hunt ngt n- nteract ng	prote n	1-re ated	prote n 1.35 1.58
DNA	topo somerase	2-a pha 1.34 1.36
Ser ne-prote n	k nase	ATM 1.32 1.39
RNA-b nd ng	prote n	14 1.31 1.39
60S	r bosoma 	prote n	L18a 1.30 2.17
Prote n	transport	prote n	Sec24A 1.30 1.34
40S	r bosoma 	prote n	S3 1.28 3.47
Phosphomeva onate	k nase 1.27 1.81
60S	r bosoma 	prote n	L27 1.25 2.10
Sort ng	nex n-3 1.24 1.32
Guan ne	nuc eot de-b nd ng	prote n	subun t	beta-2- ke	1 1.23 2.95
60S	r bosoma 	prote n	L7a 1.20 2.06
60S	ac d c	r bosoma 	prote n	P0;60S	ac d c	r bosoma 	prote n	P0- ke 1.20 2.20
60S	r bosoma 	prote n	L9 1.20 1.51
Pre-mRNA-sp c ng	factor	ATP-dependent	RNA	he case	PRP16 1.19 2.85
Inos to 	po yphosphate	5-phosphatase	OCRL-1 1.19 1.83
40S	r bosoma 	prote n	S19 1.18 2.19
Sarco emma 	membrane-assoc ated	prote n 1.17 1.78
60S	r bosoma 	prote n	L23a 1.16 1.55
40S	r bosoma 	prote n	S12 1.13 1.44
Trans ocon-assoc ated	prote n	subun t	de ta 1.12 1.60
Prote n	phosphatase	1G 1.10 2.44
Tubu n	beta-4B	cha n 1.09 2.82
40S	r bosoma 	prote n	S5;40S	r bosoma 	prote n	S5,	N-term na y	processed 1.08 1.75
60S	r bosoma 	prote n	L3 1.07 2.03
E ongat on	factor	1-de ta 1.07 2.24
40S	r bosoma 	prote n	S16 1.06 2.13
Heat	shock	prote n	105	kDa 1.06 1.36
DmX- ke	prote n	2 1.06 2.76
40S	r bosoma 	prote n	S23 1.06 2.08
40S	r bosoma 	prote n	S3a 1.05 2.02
Ser ne	pa m toy transferase	1 1.03 1.78
Tubu n	beta	cha n 1.03 1.90
U5	sma 	nuc ear	r bonuc eoprote n	40	kDa	prote n 1.02 1.39
Staphy ococca 	nuc ease	doma n-conta n ng	prote n	1 1.01 1.62
Co d- nduc b e	RNA-b nd ng	prote n 1.00 1.38
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NSCLC Pleural Fluid Neutrophils versus Healthy Donor Controls 
 
Protein	names Log2	fold	change -Log10	p-value
Inter euk n-1	receptor	accessory	prote n 3.12 1.59
EGF- ke	modu e-conta n ng	muc n- ke	hormone	receptor- ke	2 3.04 3.28
Gamma-eno ase 2.92 1.37
Pro y 	4-hydroxy ase	subun t	a pha-1 2.82 1.65
Interferon	gamma	receptor	1 2.71 1.52
A ka ne	phosphatase,	t ssue-nonspec f c	 sozyme 2.42 1.78
M crotubu e-act n	cross- nk ng	factor	1,	 soforms	1/2/3/5 2.14 1.96
Import n	subun t	a pha-4 2.12 1.87
G utam ne	synthetase 2.04 2.04
Sarco emma 	membrane-assoc ated	prote n 1.98 2.31
Interce u ar	adhes on	mo ecu e	1 1.83 1.97
Ga ect n-8 1.78 1.51
GTP:AMP	phosphotransferase	AK3,	m tochondr a 1.73 2.15
A pha-1-ant chymotryps n;A pha-1-ant chymotryps n	H s-Pro- ess 1.69 2.15
Methy osome	prote n	50 1.64 1.40
Surfe t	 ocus	prote n	4 1.62 1.45
Catecho 	O-methy transferase 1.49 1.38
Cu n-2 1.40 1.66
UDP-g ucose	6-dehydrogenase 1.39 1.64
Tr carboxy ate	transport	prote n,	m tochondr a 1.36 1.44
Anc ent	ub qu tous	prote n	1 1.33 1.51
E3	ub qu t n-prote n	 gase	TRIM33 1.28 1.36
Pept dy -pro y 	c s-trans	 somerase	FKBP5 1.26 1.35
Interferon- nduced	GTP-b nd ng	prote n	Mx2 1.23 1.50
NAD-dependent	prote n	deacy ase	s rtu n-5,	m tochondr a 1.13 1.73
N cot nam de	phosphor bosy transferase 1.04 2.72
6-phosphofructo-2-k nase/fructose-2,6-b sphosphatase	2 1.03 1.42
Noda 	modu ator	2;Noda 	modu ator	3 1.02 1.55
Ethano am ne-phosphate	cyt dy y transferase 1.01 1.57
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Protein	names Log2	fold	change -Log10	p-value
Pept dy -pro y 	c s-trans	 somerase	FKBP3 -1.01 1.80
NHL	repeat-conta n ng	prote n	3 -1.04 1.43
Prote n	S100-A12;Ca c term n -1.09 1.44
Lysosoma 	a pha-mannos dase -1.10 1.46
Prote n	FAM91A1 -1.22 1.97
Phosphat dy nos to 	4,5-b sphosphate	3-k nase	cata yt c	subun t	gamma	 soform -1.24 1.32
Tyros ne-prote n	k nase	JAK1 -1.26 1.39
Cyste ne-r ch	secretory	prote n	LCCL	doma n-conta n ng	2 -1.26 1.96
PDZ	and	LIM	doma n	prote n	5 -1.26 1.59
Transcr pt ona 	repressor	CTCF -1.29 1.83
Cyste ne-r ch	secretory	prote n	3 -1.32 1.72
Oxoe cosano d	receptor	1 -1.33 1.81
MAGUK	p55	subfam y	member	7 -1.35 3.89
Prote n	b cauda 	D	homo og	2 -1.36 1.37
Membrane	cofactor	prote n -1.42 2.06
Transmembrane	channe - ke	prote n	8 -1.42 1.77
Lymphocyte	ant gen	75 -1.54 1.32
Meva onate	k nase -1.56 1.64
Ga ect n-3-b nd ng	prote n -1.64 2.00
Nespr n-3 -1.70 2.33
Guan ne	nuc eot de	exchange	factor	VAV3 -1.72 3.51
Transcr pt on	factor	BTF3	homo og	4 -1.74 1.75
Ox d zed	 ow-dens ty	 poprote n	receptor	1 -1.89 1.83
40S	r bosoma 	prote n	S9 -1.91 2.35
DENN	doma n-conta n ng	prote n	2D -2.06 2.00
CSC1- ke	prote n	1 -2.26 1.33
60S	r bosoma 	prote n	L13 -2.38 1.61
Op o d	growth	factor	receptor -2.46 2.40
Cytoso c	carboxypept dase	1 -2.50 2.00
F-box	on y	prote n	50 -2.63 1.68
Apo poprote n	A-I;Proapo poprote n	A-I;Truncated	apo poprote n	A-I -2.74 1.53
Immunog obu n	superfam y	member	2 -2.75 1.54
Prote n	PBDC1 -2.90 1.60
COMM	doma n-conta n ng	prote n	2 -3.97 1.52
